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AbsTrACT
These consensus guidelines were jointly commissioned 
by the British Society of Gastroenterology (BSG), the 
Association of Coloproctology of Great Britain and 
Ireland (ACPGBI) and Public Health England (PHE). 
They provide an evidence- based framework for the 
use of surveillance colonoscopy and non- colonoscopic 
colorectal imaging in people aged 18 years and over. 
They are the first guidelines that take into account the 
introduction of national bowel cancer screening. For the 
first time, they also incorporate surveillance of patients 
following resection of either adenomatous or serrated 
polyps and also post- colorectal cancer resection. They are 
primarily aimed at healthcare professionals, and aim to 
address:
1. Which patients should commence surveillance post- 
polypectomy and post- cancer resection?
2. What is the appropriate surveillance interval?
3. When can surveillance be stopped?
The Appraisal of Guidelines for Research and Evaluation 
(AGREE II) instrument provided a methodological 
framework for the guidelines. The BSG’s guideline 
development process was used, which is National 
Institute for Health and Care Excellence (NICE) 
compliant.
The key recommendations are that the high- risk criteria 
for future colorectal cancer (CRC) following polypectomy 
comprise either:
 ► two or more premalignant polyps including at least 
one advanced colorectal polyp (defined as a serrated 
polyp of at least 10 mm in size or containing any 
grade of dysplasia, or an adenoma of at least 10 mm 
in size or containing high- grade dysplasia); or
 ► five or more premalignant polyps
This cohort should undergo a one- off surveillance 
colonoscopy at 3 years. Post- CRC resection patients 
should undergo a 1 year clearance colonoscopy, then a 
surveillance colonoscopy after 3 more years.
InTroduCTIon
Colorectal cancer (CRC) is a major cause of 
morbidity and mortality in the UK: more than 
40 000 people are diagnosed and more than 16 000 
people die from the disease each year.1 The vast 
majority of CRCs arise from premalignant polyps, a 
process that takes many years.2 Endoscopic polyp-
ectomy is effective in reducing CRC incidence and 
mortality.3
Some patients who have premalignant polyps 
(adenomas or serrated polyps) detected at colo-
noscopy are more likely to develop metachro-
nous polyps or CRC.4–6 Endoscopic follow- up of 
patients with such polyps is referred to as a post- 
polypectomy surveillance colonoscopy. Likewise, 
people who have had a CRC resection may develop 
a metachronous CRC and are offered post- CRC 
resection colonoscopic surveillance. Surveillance 
aims to detect and resect metachronous prema-
lignant polyps and to detect lesions not identified 
on the initial examination, thereby preventing 
cancer and reducing CRC mortality; however, no 
randomised trial has directly assessed the benefit 
of post- polypectomy or post- cancer resection 
surveillance.
Premalignant polyps are common, occurring in a 
quarter to a half of all people of screening age,7–10 
yet only about 5% of the population will develop 
CRC during their life; thus, only a minority of 
people with polyps will develop CRC, meaning that 
most people will not benefit from post- polypectomy 
surveillance. Indeed, it is an increasingly held view 
that the greatest benefit in terms of CRC preven-
tion is derived from the initial polypectomy, rather 
than from subsequent surveillance. It is possible to 
stratify individuals according to future CRC risk 
and identify cohorts of patients with persistently 
elevated CRC risk beyond index polypectomy,11 12 
yet even with current risk stratification, surveil-
lance places a considerable burden on patients and 
endoscopy services; approximately 15% of the half 
a million colonoscopies performed each year in the 
UK are performed for polyp surveillance.13
AIms And objeCTIves
These guidelines were jointly commissioned by 
the British Society of Gastroenterology (BSG), the 
Association of Coloproctology of Great Britain and 
Ireland (ACPGBI) and the English Bowel Cancer 
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Screening Programme (BCSP) (Public Health England; PHE) 
and supported by NHS England (NHSE).
These guidelines consider the use of surveillance colonoscopy 
and non- colonoscopic colorectal imaging in people aged 18 and 
over and are an update of current BSG/ACPGBI post- polypectomy 
and post- CRC resection colorectal surveillance guidelines (first 
published in 2002, last revised in 2010 (containing evidence up 
to 2006))14 15 ; they are the first guidelines that take into account 
the introduction of national bowel cancer screening. For the first 
time, they also incorporate surveillance of patients following 
resection of either adenomatous or serrated polyps, and serve as 
an update on the surveillance recommendations in the BSG 2017 
position statement on serrated polyps in the colon and rectum.6 
They are primarily aimed at healthcare professionals contrib-
uting to the management of such patients.
The high- level aims of the guidelines are to address:
1. Which patients should commence surveillance post- 
polypectomy and post- cancer resection?
2. What is the appropriate surveillance interval?
3. When can surveillance be stopped?
These guidelines do not address surveillance in patients 
affected by hereditary colorectal syndromes, guidelines for which 
have also been updated recently16 ; however, care has been taken 
to ensure consistency, avoid overlap and ensure that all patient 
cohorts are comprehensively covered by one of these guidelines.
meThods
The Appraisal of Guidelines for Research and Evaluation 
(AGREE II) instrument provided a methodological framework 
for the development of the guidelines.17 The BSG’s guideline 
development process was used, which is National Institute for 
Health and Care Excellence (NICE) compliant.18
Guideline development group
A guideline development group (GDG)—including epidemiol-
ogists, gastroenterologists, endoscopists, colorectal surgeons, 
gastrointestinal (GI) pathologists, GI radiologists, patient repre-
sentatives, charity representatives, representatives from the 
English BCSP, a health economist and a methodologist—was 
selected in accordance with BSG/NICE criteria to ensure wide 
ranging expertise across all relevant disciplines. The surgical 
and histopathological representatives were nominated by the 
ACPGBI and the Royal College of Pathologists, respectively. All 
members completed a conflicts of interest form at the outset; no 
significant conflicts were identified.
The guideline development process included meetings, 
telephone conferences, online discussions and voting among 
members of the GDG between September 2017 and June 2019.
Key guidelines questions
The initial step of the GDG process was to compile a long list of 
potential questions to be covered by the guidelines. These were 
subsequently discussed and revised in an iterative process, until 
the final list was produced:
1. What are the aims and principles of post- polypectomy and 
post- cancer resection surveillance?
2. Who should be commenced on post- polypectomy surveil-
lance?
a. Which polyp factors confer higher future risk of CRC?
i. Multiplicity
ii. Size
iii. Morphology
iv. Histological subtype (degree of villous component in 
adenomas)
v. Dysplasia grade
vi. Colonic location
b. Which patient factors confer higher future risk of CRC?
i. Age
ii. Sex
iii. Body mass index (BMI)
iv. Smoking
v. Family history of CRC
c. Which colonoscopic factors confer higher future risk of 
CRC?
i. Completion to caecum
ii. Bowel prep quality
iii. Endoscopist quality
iv. Enhanced detection technologies
d. How should such factors be used to stratify risk and pro-
duce a composite surveillance strategy?
e. Can a risk threshold be set to determine who requires 
surveillance?
3. At what interval(s) should surveillance be performed?
4. Ongoing surveillance
a. Can the findings at index and first surveillance (S1) colo-
noscopies be used to determine who needs a second sur-
veillance (S2)?
b. When (and in whom) can surveillance be stopped?
i. Relating to patient age/comorbidity
ii. Relating to colonoscopy findings
5. Special situations
a. Are special considerations required for patients who are 
below the national bowel cancer screening lower age lim-
it?
b. How does the quality of index colonoscopy affect sur-
veillance recommendations?
6. Other surveillance cohorts
a. How should surveillance be performed following surgical 
resection of CRC?
b. How should surveillance be performed following endo-
scopic resection of CRC?
c. How can serrated polyp follow- up be incorporated into 
these guidelines?
d. How should these guidelines integrate with the BSG/
ACPGBI Large Non- Pedunculated Colorectal Polyp (LN-
PCP) guidelines19 ?
e. How should these guidelines integrate with the BSG/
ACPGBI Hereditary CRC guidelines?16
7. Other surveillance modalities
a. Can CT colonography (CTC) be used for surveillance?
b. Can faecal immunochemical testing (FIT) be used for sur-
veillance?
c. Can colon capsule be used for surveillance?
d. How does the risk of cumulative radiation dose balance 
with CRC risk in CTC surveillance?
8. Other questions
a. What are the risks associated with surveillance colonos-
copy?
b. What information should the patient receive and how 
should patients be involved in the surveillance process?
c. How should polyp size be measured?
d. How does optical diagnosis of polyp type align with the 
guidelines?
e. How should the guidelines be implemented?
f. What is the anticipated change in workload from these 
surveillance guidelines?
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g. What are the key unanswered research questions?
128 clinical questions were created from the long- list of guide-
lines questions (online supplementary appendix 1).
PICos
The key guidelines questions were, where appropriate, framed 
as PICO statements (Patients, Interventions, Controls and 
Outcomes) to structure subsequent literature searches. One 
hundred and seven PICOs were developed (online supplemen-
tary appendix 1).
evidence synthesis
An expert evidence synthesis team (School of Health and Related 
Research (ScHARR), Sheffield University) was commissioned to 
provide systematic reviews, narrative summaries and evidence 
statements for the central questions (2 to 4 above; online supple-
mentary appendix 2).
The systematic review was undertaken in accordance with 
the general principles recommended in the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses (PRISMA) 
statement. A systematic literature search was performed to 
identify all published evidence relevant to the review questions. 
The search was undertaken in accordance with the parameters 
stipulated within the NICE guidelines manual. Databases were 
searched using relevant medical subject headings, free- text 
terms and study design filters (such as randomised controlled 
trial (RCT), systematic review and observational study), where 
appropriate. In addition to assessing the evidence from electronic 
database- searching, evidence reported in existing guidelines, 
which met the inclusion criteria, were checked for inclusion in 
the review.14 15 20 Returned abstracts and articles were reviewed 
for relevance with additional references obtained from cross- 
referencing of references and recommendations from the GDG. 
The consideration of articles published only in abstract form 
was only undertaken in exceptional circumstances (ie, where the 
article was of particular relevance in an area where evidence was 
scarce).
After identifying eligible studies for inclusion, methodological 
quality of the studies was assessed using the Quality In Prognosis 
Studies (QUIPS) tool for studies of prognostic factors, and a 
Cochrane risk of bias tool for non- randomised studies (ROBINS) 
of interventions, where applicable. Data were extracted into a 
piloted data extraction form by one reviewer and checked by 
a second reviewer. Information on study characteristics and 
methods, participant characteristics, interventions and compara-
tors evaluated, and clinical outcomes was extracted.
A narrative summary of included studies was undertaken, 
including tabulation of relevant study information and a Grading 
of Recommendations, Assessment, Development and Evalua-
tions (GRADE) assessment of the evidence, from which a draft 
evidence statement was written.
Subgroups of the GDG performed similar systematic reviews, 
narrative summaries and evidence statements for the other ques-
tions. Additional relevant publications were considered at the 
discretion of the GDG, up until June 2019.
Details of the GDG search strategies are provided in online 
supplementary appendix 3.
delphi consensus
The evidence statement, narrative summary and supporting 
references for each guideline question were uploaded onto a 
bespoke guidelines web platform (ECD Solutions, USA), which 
was used to facilitate the guideline development process.
Each evidence statement and narrative summary was reviewed 
and voted on in anonymised fashion by each member of the GDG 
using a 5- point scale (strongly agree, agree, neutral, disagree, 
strongly disagree) in a primary voting round. GDG members 
were encouraged to add comments and cite other relevant refer-
ences. Consensus was considered reached when either ≥80% 
participants agreed or, in the final round, where≥50% agreed 
and <20% disagreed.
Two subsequent face- to- face meetings were held to discuss 
the results and, where appropriate, revise, merge or refine the 
statements. These statements were then re- voted on, leading to 
further statement modifications. In total, three rounds of voting 
were held for statements relating to the evidence.
Email discussions and two subsequent teleconferences were 
held to construct a draft surveillance algorithm and guidelines 
recommendations. These were subsequently voted on over three 
further consensus voting rounds, including at a final face- to- face 
meeting in June 2019.
GrAde
The GRADE tool was used to evaluate the guideline. Where an 
evidence GRADE was inappropriate, “Good Practice Recom-
mendations” were made at the discretion of the GDG.21 This 
categorises both the strength of evidence and the strength of a 
recommendation following consensus by an expert panel. While 
the strength of recommendation may often reflect the evidence 
base, the GRADE system allows for occasions where this is not 
the case, for example where there appears good sense to make a 
recommendation in spite of an absence of high- quality scientific 
evidence such as a large RCT.
definitions
The following definitions are used in these guidelines.
Serrated polyp—The umbrella term used to describe hyper-
plastic polyps, sessile serrated lesions (SSLs), SSLs with dysplasia 
(SSLd), traditional serrated adenomas (TSA) and mixed polyps.6
Premalignant polyp—The term includes both serrated polyps 
(excluding diminutive (1–5 mm) rectal hyperplastic polyps) and 
adenomatous polyps. It does not include other polyps such as 
post- inflammatory polyps.
Advanced serrated polyp—A serrated polyp of at least 10 mm 
in size or containing any grade of dysplasia.
Advanced adenomatous polyp (synonymous with advanced 
adenoma)—An adenoma of at least 10 mm in size or containing 
high- grade dysplasia. Note: international definitions also include 
tubulovillous or villous histology, but these are not part of the 
UK definition.
Advanced colorectal polyp—The term includes both advanced 
serrated polyps and advanced adenomatous polyps.
Advanced neoplasia—This term has been used historically to 
describe the combination of advanced adenomas and colorectal 
cancers. The GDG feels that the term is outmoded, first because 
it does not include lesions from the serrated pathway, and second 
because it combines two entities that have very different clin-
ical significance. However, as advanced neoplasia has been used 
extensively in the past as an outcome measure, the term was used 
as an search term in the evidence synthesis.
resulTs
surveillance principles
 ► Some but not all colorectal polyps have malignant potential.
 ► Some but not all patients with previous polyps are at 
increased risk of recurrent polyps and thus CRC.
 o
n
 June 19, 2020 at BVA. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319858 on 27 November 2019. Downloaded from 
204 Rutter MD, et al. Gut 2020;69:201–223. doi:10.1136/gutjnl-2019-319858
Guidelines
 ► The primary aim of post- polypectomy and post- CRC resec-
tion surveillance is to reduce CRC incidence in patients 
found to have prior colonic neoplasia, once neoplasia clear-
ance has been achieved. This is achieved through the subse-
quent identification and resection of de novo and missed 
polyps, thereby preventing these lesions from progressing to 
CRC.
 ► The secondary aim of post- polypectomy and post- CRC 
resection surveillance is to reduce CRC mortality. This is 
achieved both through the subsequent identification and 
resection of de novo and missed polyps, thereby preventing 
these lesions from progressing to CRC (ie, by reducing CRC 
incidence) and through the identification of CRC at an 
earlier stage when prognosis is better.
 ► Surveillance should only be offered to individuals who 
remain at higher risk of developing CRC, beyond the reduc-
tion seen by index polyp clearance, as compared with the 
general population.
 ► Surveillance should be undertaken at the minimum frequency 
required to deliver these aims.
 ► Surveillance should not be continued unless there is evidence 
that ongoing surveillance is required to deliver these aims.
 ► The need for post- polypectomy surveillance is best deter-
mined by comparing the long- term CRC risk of a defined 
cohort of post- polypectomy patients not undergoing surveil-
lance with that of an age- and sex- matched general popula-
tion comparator group.
 ► The effectiveness of post- polypectomy surveillance is best 
determined by comparing the long- term CRC risk of a 
defined cohort of post- polypectomy patients undergoing 
surveillance with that of an age- and sex- matched general 
population comparator group.
 ► Where long- term CRC data are not available, the findings at 
surveillance may be used as a surrogate means to determine 
the need for post- polypectomy surveillance, although this 
method is inferior.
 ► Surveillance risk stratification is predicated on an assump-
tion that the initial colonoscopy is of an acceptable minimum 
quality, defined as complete colonoscopy to the caecum with 
at least adequate bowel preparation, and with clearance of 
all identified premalignant polyps.
 ► The findings at surveillance comprise both de novo 
pathology and pathology missed or incompletely excised at 
the prior colonoscopy.
 ► Higher quality colonoscopy reduces the proportion of 
pathology that is missed or incompletely excised, hence 
reduces that patient’s future CRC risk.
 ► The impact of surveillance in terms of CRC risk reduction 
should be balanced with the risks of harm (for example, 
colonoscopy complications or psychological distress) and 
the costs to both the health service and patients.
 ► Patients should be offered surveillance based on the best 
available evidence. The benefits and risks of surveillance 
should be explained to patients, who should be involved 
in shared decision- making. The risks and benefits of non- 
adherence to surveillance should also be explained.
The GDG reached the above important principles and prereq-
uisites underpinning colonoscopic surveillance by consensus. 
While reducing CRC mortality is an important aim of surveil-
lance, the main aim of surveillance is to prevent CRC by resecting 
premalignant polyps.
Clearing the colon of premalignant polyps is a powerful tool 
in the prevention of CRC and probably more important than 
subsequent surveillance; as evidenced in these guidelines, many 
patients benefit from this alone and do not require surveillance. 
Reducing unnecessary surveillance colonoscopies benefits those 
patients by reducing their exposure to the inconvenience and risk 
of the procedure. Moreover, in a resource- constrained health-
care system, it frees up resource for others who would benefit 
more from undergoing colonoscopy. However, while this health 
economic aspect was a consideration, we did not consider it the 
primary one for these guidelines, which was to develop guidelines 
for those people who demonstrably benefit from surveillance. 
There is an important distinction to be made between performing 
a colonoscopy on a symptomatic patient, where the potential 
benefit is immediate, and performing a surveillance colonos-
copy, where there is seldom any immediate benefit (the patient is 
asymptomatic and highly unlikely to have malignancy at the time 
of surveillance); rather the potential for benefit (future cancer 
prevention by removing asymptomatic premalignant polyps) 
is only realised many years (over a decade on average) into the 
future due to the slow polyp- cancer progression timeline.
While much of the literature on post- polypectomy surveil-
lance analyses surrogate endpoints of advanced pathology found 
by surveillance, the GDG acknowledged that, where available, 
evidence relating to long- term CRC incidence (or mortality) should 
be afforded greater importance. The GDG considered setting a 
minimum threshold for advanced colorectal polyp yield at surveil-
lance to indicate that such surveillance procedures were indeed 
worthwhile, with discussion suggesting that a yield of approx-
imately 10% for advanced colorectal polyps might be sufficient 
to justify surveillance. However, although the GDG agreed that 
setting a threshold would be helpful, consensus was not reached.
The GDG considered it vital to stress the importance of a high- 
quality index colonoscopic procedure: improving the quality 
of mucosal visualisation at colonoscopy above the acceptable 
minimum results in increased detection of adenomas and sessile 
serrated lesions and a reduction in missed pathology. Where the 
bowel preparation is poor, or the colonoscopy incomplete, the 
clinician should aim for early re- examination, rather than relying 
on future surveillance to detect missed lesions. Careful polyp-
ectomy using optimal technique to ensure complete and safe 
excision is also an important aspect of a high- quality index colo-
noscopic procedure.22 The GDG considered that a shift in ethos 
to a higher quality index procedure with more selective and less 
frequent surveillance was desirable. There is clear evidence that 
patients of higher adenoma- detecting endoscopists have lower 
post- colonoscopy CRC incidence and mortality rates.23 24 Low- 
detecting endoscopists expose their patients to “double unpro-
tection”: not only are lesions left in situ, but also the patient’s 
need for surveillance may be underestimated.25 26 High detection 
rates can only be achieved by a slow, meticulous inspection tech-
nique. Enhancement or modifications to colonoscopy technique 
(eg, chromoendoscopy) or technology (eg, artificial intelligence, 
or endoscopic caps and cuffs) may further reduce pathology miss- 
rates, although the clinical significance of the additional lesions 
detected by these enhanced techniques is uncertain and requires 
further research on the longer- term impact on post- colonoscopy 
CRC.
Patient views should be considered when determining the most 
appropriate surveillance strategy. The National Health Service 
(NHS) Constitution states that, where appropriate, patients should 
be involved in all decisions about their care and treatment. It has 
been shown that patients are more likely to attend for a proce-
dure if they understand why it is being performed and what it 
will entail. It has been reported that endoscopists underestimate 
the value of clear communication and shared decision- making. 
The National Quality Board indicates strong links between being 
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Figure 1 British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England (BSG/ACPGBI/PHE) 
post- polypectomy and post- colorectal cancer resection surveillance guideline algorithm. LNPCP, large non- pedunculated colorectal polyp; NPCPs, non- 
pedunculated colorectal polyps; y, years.
involved in the decision- making process and improved safety and 
better clinical outcomes. However, there is a paucity of evidence 
regarding patient views on, and experiences of, surveillance. This 
is consistent with the lack of research regarding patient views and 
experiences of endoscopy, and is an area that requires significant 
research.27 28
Patients should have the evidence for surveillance explained 
to them and risks and benefits of different strategies explained. 
The principles of shared decision- making and informed choice 
should be applied. Patients should also be made aware of any 
alternative strategy available, and a discussion should take place 
regarding risks and benefits. Patient needs and expectations 
should be kept in mind and addressed where possible.
Patients should be made aware of other evidence- based interven-
tions that could reduce their risk of CRC and/or polyp recurrence. 
These could include lifestyle and behavioural modifications (eg, 
stopping smoking and reducing red meat consumption) as well as 
medications (eg, aspirin).
Information should be conveyed in a manner and language that 
is understandable, allowing patients to make informed choices. 
Information should be provided in clear written form and with 
clear verbal explanation and opportunity for reflection and discus-
sion. Patients should be made aware of whom they can contact in 
the event of any subsequent questions about surveillance.
surveillance guidelines recommendations
The following recommendations have been developed by the 
GDG, based on the predetermined surveillance principles, the 
underlying evidence and following detailed discussion and 
consensus voting. These recommendation are summarised in 
figure 1.
We recommend that the high- risk criteria for future CRC 
comprise either:
 ► two or more premalignant polyps including at least one 
advanced colorectal polyp (defined as a serrated polyp of 
at least 10 mm in size or containing any grade of dysplasia, 
or an adenoma of at least 10 mm in size or containing high- 
grade dysplasia); or
 ► five or more premalignant polyps.
GRADE of evidence: See later evidence section 
Strength of recommendation: Strong
The guidelines incorporate surveillance of patients following 
resection of either adenomatous or serrated polyps, aiming 
to simplify risk stratification of patients who may have both 
types of polyp. Surveillance following resection of CRC and 
LNPCPs have also been incorporated into the same algorithm 
in order to standardise surveillance across these broad cohorts 
of patients.
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The high- risk criteria are based on the GRADE evidence 
synthesis detailed later in this manuscript, and follow detailed 
discussion among the GDG. The evidence suggests that while 
patient factors influence the likelihood of developing prema-
lignant polyps in the first place, prediction of polyp recurrence 
is better determined by the index polyp findings, presumably 
because these crystallise the overall patient risk, and by the 
quality of the index colonoscopy. One of the key new criteria 
is that patients (except for the post- CRC/LNPCP cohorts) need 
to have had at least two premalignant polyps to qualify for 
surveillance.
Although there is evidence to suggest that index colonos-
copy findings of adenoma with tubulovillous/villous histology 
is associated with an increased risk of advanced adenomas (AA), 
advanced neoplasia (AN) and CRC at first surveillance, tubu-
lovillous/villous histology has not been included in the algo-
rithm. Tubulovillous/villous histology has never been included in 
previous UK post- polypectomy guidelines, due to the well docu-
mented lack of inter- observer agreement among histopatholo-
gists in the assessment of villous architecture.29 30 The GDG felt 
the inclusion of tubulovillous/villous histology in the guidelines 
was not justified, given the additional surveillance workload that 
would be generated; this view is supported by the recent large 
study by Atkin et al31 32 of individuals undergoing surveillance 
for intermediate grade adenomas detected in the symptomatic 
service, where tubulovillous/villous histology was not a risk 
factor for long- term CRC risk.
We suggest that where histological completeness of excision 
cannot be determined in patients with non- pedunculated polyps 
of 10–19 mm in size, or an adenoma containing high- grade 
dysplasia, or a serrated polyp containing any dysplasia, then a 
site- check should be considered within 2–6 months. The need 
for subsequent surveillance should then be determined based on 
the high- risk surveillance criteria.
GRADE of evidence: Low 
Strength of recommendation: Weak
Careful polypectomy using optimal technique to ensure 
complete and safe excision is an important aspect of a high- 
quality index colonoscopic procedure. The role of site checks 
for lesions <20 mm in size is less robust than for larger lesions; 
however, there are clear data that the risk of incomplete exci-
sion, even for endoscopists who know they are being observed, 
is higher than expected (10.1%), and that this risk is higher for 
large (10–20 mm) than small (5–9 mm) neoplastic polyps (17.3% 
vs 6.8%; relative risk (RR) 2.1), and that sessile serrated lesions 
are at higher risk of incomplete excision than adenomatous 
polyps (RR 3.7).22 Cancers thought to have arisen in sessile 
serrated lesions are also over- represented in interval cancer 
series, also suggesting that either missed or incompletely resected 
sessile serrated lesions may explain some post- colonoscopy 
CRCs (PCCRCs).33 In a recent study that looked at neoplasia 
within the same colonic segments after resection of a 10–20 mm 
sized polyp, the estimated rate of incomplete resection for non- 
pedunculated polyps was higher (18.3%, 95% CI 14.2 to 22.5) 
than for pedunculated polyps (3.5%, 95% CI –0.7 to –11.3).34 
Thus, the GDG considered that a shift in ethos to more careful 
polypectomy, supported by selected site checks, may enable 
less frequent surveillance. It is hoped that ultimately this might 
also help drive better polypectomy and improved histological 
reporting.
We recommend that polyp size should be recorded as the 
largest dimension of neoplastic tissue (adenoma or serrated) 
as measured at histopathological examination. For piecemeal 
resection or where there has been fragmentation of tissue during 
retrieval, endoscopic assessment of size should be used.
GRADE of evidence: Moderate 
Strength of recommendation: Strong
Current evidence suggests that there is significant inter- observer 
variation between colonoscopists in estimation of polyp size and 
that size in situ is often underestimated by visual inspection.35 
Various methods of improving size estimation in situ through 
comparison against endoscopic accessories of standard size have 
been proposed, though results have been conflicting.36 37 Polyp 
size estimation at CTC is also known to be variable in comparison 
to colonoscopic and histopathology size and subject to reader- 
related and technical factors.38 39 Studies have also demonstrated 
significant variation between the size in situ, pre- fixation in 
formalin and post- fixation at histopathology.40 The size of polyp 
that is considered most significant when assigning surveillance 
intervals is generally considered to be 10 mm, as most surveillance 
guidelines use this threshold as a major criterion for assignment 
of surveillance category41–43; therefore accurate recording of 
size is essential. Size of polyps resected en bloc as estimated at 
histopathology is considered to demonstrate the least variation 
in assignment of colonoscopic surveillance category,40 and each 
type of measurement (in situ, pre- fixation and post- fixation) will 
have a proportion of cases that will be assigned to a less or more 
frequent surveillance category in comparison. The phenomenon 
of terminal digit preference is also known to occur with both 
colonoscopic, radiologic as well as histopathologic estimation of 
polyp size whereby the precise polyp size tends to be rounded off 
to the nearest digit ending with zero.40 44 Piecemeal resection of 
polyps, and particularly larger polyps, is associated with difficul-
ties in accurate estimation of polyp size, and is not considered 
to be relevant to this statement as it generally does not have an 
impact on assigning surveillance categories (since such polyps are 
usually at least 10 mm).
In conclusion, polyp size estimation at histopathology provides 
the least variation (narrower confidence intervals) in assignment 
of surveillance category, and most consistency for estimating size 
of polyps resected en bloc at colonoscopy. Therefore, the polyp 
size used for assigning surveillance intervals should be that of 
the neoplastic portion measured at histopathologic examination 
rather than from visual estimation at colonoscopy for polyps 
resected and retrieved en bloc.
We recommend that people with high- risk findings on index 
colonoscopy who are under the age of 75 years should have a 
surveillance colonoscopy performed after an interval of 3 years 
(note the one exception in the next statement).
GRADE of evidence: Low 
Strength of recommendation: Strong
We suggest that due to the long timeline from a clearance 
colonoscopy through the potential development of new polyps 
to the possible development of a symptomatic cancer, surveil-
lance should only be performed in people whose life- expectancy 
is greater than 10 years, and in general not in people older than 
about 75 years.
GRADE of evidence: Low 
Strength of recommendation: Weak
We recommend that people with no high- risk findings on 
index colonoscopy should not undergo colonoscopic surveil-
lance, but should be strongly encouraged to participate in their 
national bowel screening programme when invited (note the one 
exception in the next statement).
GRADE of evidence: Low 
Strength of recommendation: Strong
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We suggest that people with premalignant polyps but no high- 
risk findings on index colonoscopy, who are more than 10 years 
younger than the national bowel screening programme lower 
age- limit, should be considered for a surveillance colonoscopy 
performed after an interval of 5 or 10 years, individualised to 
their age and other risk factors.
GRADE of evidence: Low 
Strength of recommendation: Weak
As outlined in our surveillance principles, not all patients with 
previous polyps are at increased risk of future CRC (indeed due 
to polyp clearance, many are at lower risk than the general popu-
lation), and therefore not all patients benefit from colonoscopic 
surveillance. These guidelines are the first to be published since 
the introduction of general population bowel cancer screening 
in the UK. As stated in the previous iteration, participation in 
population screening will be sufficient for many people post- 
clearance colonoscopy, and is therefore appropriate management 
for people without high- risk criteria who are of screening age.
The GDG felt that with the tighter, newly redefined surveil-
lance criteria, all qualifying patients should form a single surveil-
lance cohort and should undergo surveillance at an interval of 
3 years. The evidence underpinning the GDG’s selection of a 
3 year interval is detailed later in these guidelines. The GDG 
notes that a large RCT (the EPOS trial;  ClinicalTrials. gov Iden-
tifier NCT02319928) is underway to assess the suitability of a 
5 year interval for high- risk cohorts.
While there is no direct evidence from surveillance studies for 
what age or estimated life- expectancy surveillance can be stopped 
without increasing the risk of future CRC development, there is 
ample evidence, cited throughout these guidelines, that following 
a clearance colonoscopy, the vast majority of patients will not go 
on to develop a subsequent cancer. Even when this occurs, the 
timeline from the development of new polyps, through the devel-
opment of an advanced polyp, to the possible development of a 
cancer, and then for that cancer to cause symptoms (ie, to be clini-
cally relevant) is at least 10 years for most patients.45–47 Given that 
the risks associated with undergoing colonoscopy increase with 
age and comorbidity, we recommend that it is good practice not 
to perform post- polypectomy surveillance routinely on patients 
over 75 years, or where comorbidity indicates that life expectancy 
is likely to be less than 10 years48—doing so will often result in 
overtreatment (removal of benign polyps that would not affect 
the patient’s health during their lifetime). Perhaps the most perti-
nent study is a large, retrospective cohort study of colonoscopic 
surveillance in the elderly,49 which showed a significantly lower 
CRC incidence among elderly patients (over 75 years) undergoing 
surveillance compared with non- elderly patients (HR for CRC 
0.06, 95% CI 0.02 to 0.13; p<0.001), and that both age 75 years 
and older and Charlson score of 2 were independently associated 
with increased risk of postprocedure hospitalisation (adjusted 
odds ratio (OR) 1.28, 95% CI 1.07 to 1.53; p=0.006, and 2.54, 
95% CI 2.06 to 3.14; p<0.001, respectively).
Life- expectancy tools (for example https:// eprognosis. ucsf. 
edu/ calculators. php) may be used to assist decision- making in 
such patients. Where ongoing surveillance is being considered 
despite this recommendation, the patient should have the oppor-
tunity to discuss the increased risks and reduced benefits of 
undergoing surveillance with an appropriate clinician.
NICE methods evaluate cost- effectiveness to determine 
how to allocate our finite NHS resources to maximise health 
outcomes. Health outcomes are usually measured in terms of 
quality adjusted life years (QALYs) which encompass both 
survival and health- related quality of life. Public preferences 
for NHS spending are to maximise QALY gains and it follows 
that it is more cost- effective to prevent a death in a younger 
person. A health economic analysis would be required to deter-
mine whether surveillance of persons over 75 is cost- effective. 
We do know, however, that the prevention of a CRC death in a 
young person is associated with a higher QALY gain than in an 
older person due to differences in life expectancies. Therefore, 
given the same future CRC risk, surveillance will be more cost- 
effective in a younger person due to the longer life expectancy 
and associated higher QALY gain.
Despite a declining incidence of CRC for people over the 
age of 55 years in the USA, the incidence has been increasing 
in younger people, a phenomenon also seen in Europe.50 51 The 
reasons for increasing CRC risk in people under 50 years of age 
(sometimes called early onset CRC) are likely to be multifacto-
rial. As a result of these recent findings, CRC screening guide-
lines from the American Cancer Society now include a qualified 
recommendation to begin screening at age 45.52 The prevalence 
of adenomas in people aged under 50 years ranges between 
approximately 15–19% (under the age of 40 years) and 24–30% 
(40–49 years), and rates of colonoscopy are increasing in this 
age group.50 As described later in these guidelines, published 
evidence indicates that metachronous colorectal neoplasia risk 
is actually lower in younger age groups. However, there needs 
to be a balance between published epidemiological evidence and 
clinical concern about possible heterogeneous risk factors for 
CRC in a younger population who have adenomas. For example, 
some younger patients who have what appear to be sporadic 
adenomas, may benefit from additional surveillance due to 
hereditary or other risk factors which account for their young 
age of presentation.
Thus, the GDG suggests that for low- risk individuals (those 
with premalignant polyps but falling short of high- risk criteria) 
who are younger than about 40 years of age, surveillance 
should be considered on an individualised basis with other risk 
factors (such as family history) taken into consideration. Ideally, 
management should be agreed by the local surveillance lead (ie, 
a local expert) in conjunction with clinical genetics services. For 
example, if a patient with adenomas or serrated polyps (falling 
short of the high- risk criteria) is under 30 years of age or has a 
family history of CRC, a 5 year surveillance colonoscopy may be 
considered; if this surveillance colonoscopy is normal the patient 
could be discharged from colonoscopic surveillance.
The GDG acknowledges the role of the national bowel cancer 
screening programmes in providing ongoing screening of people 
who do not qualify for colonoscopic surveillance. The age range 
of national screening currently varies from nation to nation, and 
it is anticipated that the lower age limits will change over time; 
the guidelines have been written with this in mind, hence the 
“10 years younger than screening” cut- off will vary in different 
nations, and will change over time as the relevant screening 
programme for that patient alters.
Age- specific surveillance recommendations are shown in 
table 1.
We recommend that patients who have undergone a poten-
tially curative CRC resection should have a clearance colonos-
copy within a year of their diagnosis
GRADE of evidence: Low 
Strength of recommendation: Strong
We recommend that once a clearance colonoscopy has been 
performed in the postoperative period in patients who have had a 
CRC resection, their next surveillance should be performed after 
an interval of 3 years. The need for further surveillance should 
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Table 1 Post- polypectomy surveillance recommendations by age
Colonoscopy 
findings
high- risk 
criteria
low- risk (premalignant 
polyp(s)but no high- 
risk criteria) no polyps
Within national bowel 
screening age range 
or within 10 years of 
lower age limit
Colonoscopy 
after 3 years
Participate in national 
bowel screening when 
invited
Participate in 
national bowel 
screening when 
invited
More than 10 years 
younger than national 
bowel screening lower 
age limit
Colonoscopy 
after 3 years
  Consider colonoscopy 
after 5 or 10 years, 
individualised to their 
age and other risk 
factors
Participate in 
national bowel 
screening when 
invited
At least 75 years old, 
or if life expectancy 
<10 years
In general, no colonoscopic surveillance recommended
then be determined in accordance with the post- polypectomy 
high- risk criteria.
GRADE of evidence: Low 
Strength of recommendation: Strong
A recent Cochrane Review and three subsequent RCTs 
comparing different intensity follow- up regimens (including 
colonoscopic surveillance, Carcino- Embryonic Antigen (CEA) 
and/or CTC surveillance) after potentially curative resec-
tion of CRC have not shown any significant effect on overall 
survival.53–56 Two further trials have demonstrated that colo-
noscopy independently influences outcomes in terms of overall 
survival, but not with regard to cancer- specific mortality or iden-
tification of recurrence.57 58
Large published observational studies59–63 including 
population- based cancer registry studies59 64 and those that 
specifically excluded patients with Lynch syndrome65 report an 
increased risk of metachronous CRC after curative resection. 
In a cancer registry cohort study from the Netherlands, CRC 
was diagnosed in 10 283 patients after 39 974 person- years of 
follow- up.59 The presence of synchronous CRC was the only 
significant risk factor for developing metachronous CRC (RR 
13.9, 95% CI 4.7 to 41.0). However, a recent systematic review 
and meta- analysis shows that the absolute risk is substantially 
lower than 1%, ranging between 0.63% and 0.74% in the 
first 3 years of follow- up, further dropping to <0.5% after 36 
months.66
It has been suggested that more than half of the apparent 
metachronous cancers are due to missed lesions, incompletely 
resected lesions or inadequate initial examination.65 Only just 
over 5% of metachronous cancers are thought to be due to 
newly developed cancers.65 There is some evidence that a single 
colonoscopy performed following resection may be associated 
with improved survival, possibly by colorectal ‘clearance’ of 
synchronous lesions, some of which may have been missed at 
the time of diagnosis of CRC.67 In a US study of 1002 patients, 
5 year survival was higher (76.8%) for patients who had at least 
one follow- up exam than for patients who did not undergo 
follow- up (52.2%, p<0.001). However, others have questioned 
the value of the colonoscopy at 1 year, emphasising the necessity 
to have a clean colon before surveillance begins.
There is some low- quality evidence of the cost- effectiveness 
of early colonoscopic surveillance after cancer resection in a 
single study.68 In this study the number of early (1 year) colo-
noscopies needed to detect one CRC and to prevent one CRC- 
related death was 143 and 926, respectively. The incremental 
cost- effectiveness ratio was $40 313 per life- year gained by 
performing colonoscopy. However, the rate of metachronous 
cancers used in the analysis was generated from a pooled analysis 
of historical data.61
Regarding the intensity of colonoscopic follow- up, Wang 
et al69 showed that there was no survival difference between 
routine (colonoscopy at 6, 30 and 60 months postoperatively) 
and intensive (colonoscopy at 3 month intervals for 1 year, at 
6 month intervals for the next 2 years, and once a year subse-
quently) colonoscopic surveillance regimens.
The risk of metachronous cancer development is highest in 
the first 3 years after diagnosis of CRC.66 70 This increased risk is 
particularly common in older studies or in those where perioper-
ative colonoscopy was not systematically performed.70 The risk 
of metachronous CRC compared with the general population 
appears to be of the same magnitude as that following resec-
tion of high- risk precancerous lesions.70 Hence it seems logical, 
once a high quality postoperative clearance colonoscopy has 
been performed, that further follow- up should be determined 
in accordance with the post- polypectomy surveillance guidelines 
schedule.
We recommend that as recurrence rates after pathologically 
en bloc R0 endoscopic mucosal resection (EMR) or endoscopic 
submucosal dissection (ESD) of LNPCPs or early polyp cancers 
are low, no site checks are required, and the patient should 
undergo post- polypectomy surveillance after an interval of 3 
years. The need for further surveillance should then be deter-
mined in accordance with the post- polypectomy high- risk 
criteria.
GRADE of evidence: Low 
Strength of recommendation: Strong
We recommend a site check is performed 2–6 months after 
piecemeal EMR or ESD of LNPCPs (at least 20 mm in size), in 
line with BSG/ACPGBI LNPCP guidelines. A further site check 
at 18 months from the original resection is recommended to 
detect late recurrence. Once no recurrence is confirmed patients 
should undergo post- polypectomy surveillance after an interval 
of 3 years. The need for further surveillance should then be 
determined in accordance with the post- polypectomy high- risk 
criteria
GRADE of evidence: Low 
Strength of recommendation: Strong
The 2015 BSG and ACPGBI guidelines on LNPCPs recom-
mend a polypectomy site check at 2–6 months after piecemeal 
EMR19 for non- polypoid lesion ≥20 mm in size. The 2017 Euro-
pean Society of Gastrointestinal Endoscopy (ESGE) guidelines on 
polypectomy and EMR emphasised the role of en bloc resection 
either by EMR or ESD for lesions with a risk of submucosal inva-
sion and noted high rates of recurrence in larger lesions ≥40 mm 
in size.71 Early recurrence was seen by 3 months in 76% of cases, 
and 96% of cases by 6 months where studies differentiated 
between 3 and 6 month site checks, suggesting 6 months may be 
the optimal time for a site check where the polyp is thought to 
be completely resected. Late recurrence is a recognised feature 
of piecemeal EMR, where recurrence can occur even if the 
initial site check and biopsies did not show residual polyp, with 
recurrence detected beyond 6–12 months in 5–9% of cases.72 73 
Therefore, it may be prudent to reassess piecemeal EMR sites 
again at 12–18 months before returning to standard surveillance 
intervals. Some groups have attempted to use polyp and resec-
tion characteristics to stratify (Sydney Endoscopic Recurrence 
Tool—SERT), where low- risk lesions have a 12% recurrence rate 
versus 36% for higher risk lesions at 18 months.73 Most recur-
rence (>90%) can be managed endoscopically.
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Rates of recurrence after en bloc resection either by EMR 
or ESD appear very much lower than after piecemeal EMR. 
Meta- analysis suggests that the overall rate of recurrence after 
piecemeal EMR was 22% (95% CI 15% to 31%), but only 3% 
(95% CI 1% to 6%) after en bloc EMR.72 In a Japanese multi-
centre cohort, overall recurrence rates were 2.3% for en bloc 
EMR versus 11.9% for piecemeal EMR. Similarly, recurrence 
at ESD was 19 times more common if a piecemeal resection 
was performed.74 This was confirmed in a meta- analysis of 
Asian and Western ESD studies, where recurrence after en bloc 
R0 resection (microscopically margin- negative resection) was 
0.05% for 16 Asian studies and 0% for four western studies.75 
Pathological R0 resection after endoscopic excision has been 
defined as at least 50 μm clearance between dysplasia and the 
cut edge of the lesion.76 Therefore, when a lesion is resected en 
bloc and confirmed as both endoscopically and pathologically 
R0, the risk of recurrence is sufficiently low that surveillance 
can simply be carried out at the standard surveillance interval 
dictated by size and number of polyps, without the additional 
site checks at 2–6 and 12–18 months required for piecemeal 
resection, assuming the colon was comprehensively cleared of 
other lesions.
In conclusion, LNPCPs that are resected en bloc and patholog-
ically R0 have exceptionally low recurrence rates, and can safely 
return to standard surveillance. Piecemeal resection requires 
more intensive polypectomy site surveillance.
We recommend that the need for ongoing colonoscopic 
surveillance should be determined by the colonoscopic findings 
at each surveillance procedure, using the same high- risk criteria 
to stratify risk.
GRADE of evidence: Low 
Strength of recommendation: Strong
We recommend that people with high- risk findings on a 
surveillance colonoscopy should undergo a further surveillance 
colonoscopy at an interval of 3 years (with the same age- related 
caveats applied again).
GRADE of evidence: Low 
Strength of recommendation: Strong
We recommend that people with no high- risk findings on a 
surveillance colonoscopy should cease colonoscopic surveil-
lance, but should participate in the national bowel screening 
programme when invited (with the same age- related caveats 
applied again).
GRADE of evidence: Low 
Strength of recommendation: Strong
The evidence for ongoing surveillance beyond the first surveil-
lance colonoscopy is sparse and is summarised later in these 
guidelines. The GDG therefore felt that it was most appropriate 
to apply the same high- risk criteria to findings on surveillance. It 
is anticipated that this means that most people will undergo only 
one surveillance colonoscopy; this aligns with our guidelines’ 
surveillance principles of not continuing surveillance unless 
there is evidence that this is beneficial. An additional benefit is 
that this should make the guidelines easier to follow, as only 
one set of criteria is required and because clinicians need only 
consider the findings of the most recent surveillance episode.
The GDG considered extending second and subsequent 
surveillance intervals to 5 years, given the very low probability 
of missed pathology after both the index and first surveillance 
colonoscopy combined, and the slow polyp- cancer progression 
timeline. However, this option did not reach consensus. The 
EPOS trial should add further evidence for this question.
We recommend that surveillance colonoscopies should only 
be performed by colonoscopists who are either screening 
accredited, or whose colonoscopy performance measures (key 
performance indicators—KPIs) exceed the minimum standard as 
defined in the BSG lower GI quality standards publication
GRADE of evidence: Low 
Strength of recommendation: Strong
Evidence from many studies outlined in these guidelines, 
investigating the impact of colonoscopy quality, accuracy of 
polyp detection and completeness of polyp resection, suggests 
that in order to achieve optimal effectiveness from surveil-
lance, operators need to meet the relevant KPIs. This requires 
endoscopy services to emphasise and monitor achievement of 
minimum KPIs for all colonoscopists. While these guidelines 
relate to surveillance colonoscopy, it is important, as stated in 
our surveillance principles, that high- quality colonoscopy should 
apply to all colonoscopic procedures and not just to surveillance 
procedures. Moreover, the minimum standards are just that—
the minimally acceptable quality—and endoscopists and endos-
copy units should strive to achieve the higher target standards.77
We recommend that when colonic surveillance is required 
after previous polypectomy, CTC is an acceptable alternative if 
colonoscopy is incomplete or not possible due to the patient’s 
clinical condition.
GRADE of evidence: Very low 
Strength of recommendation: Strong
There is surprisingly little literature investigating the role of 
CTC for polyp surveillance specifically. A single high- quality 
multicentre prospective cohort study recruited high- risk 
patients, including a subset with previous colonic polyps.78 In 
the 343 patients with previous polypectomy, CTC was 84.2% 
sensitive and 85.3% specific for 6 mm+AN, and 90.8% sensi-
tive for 10 mm+AN. Although many other CTC diagnostic test 
accuracy studies have recruited patients with prior polypectomy, 
few report the results solely for the post- polypectomy cohort. In 
one meta- analysis,79 studies were classified as recruiting patients 
at average (ie, a screening population) or high risk (mainly 
comprising a mix of patients with symptoms, positive faecal 
occult blood testing, previous polypectomy). A separate meta- 
analysis was not performed for the 41 studies recruiting high- 
risk patients, but overall pooled sensitivity was 67% for 6–9 mm 
polyps and 87% for 10 mm+polyps, with corresponding speci-
ficities of 92% and 96%.
The ultimate goal of colonic surveillance post- polypectomy 
is to reduce subsequent CRC incidence; we found no studies 
reporting longer- term clinical outcomes of using CTC for post- 
polypectomy surveillance. A recent systematic review and meta- 
analysis reported a rate of post- imaging CRC (PICRC) at a mean 
of 34 months follow- up of 0.61 PICRCs per 1000 patient- 
years, or 4.4% when expressed as a percentage of total cancers 
detected, which is similar to analogous rates for colonoscopy.80 
However, again these studies derive from a mixed population of 
screening, symptomatic and high- risk patient cohorts rather than 
purely a surveillance population.
We recommend that when colonic surveillance is required 
after curative- intent resection of CRC, CTC should only be used 
for individuals in whom colonoscopy is contraindicated or not 
possible due to the patient’s clinical condition.
GRADE of evidence: Moderate 
Strength of recommendation: Strong
CTC is intuitively attractive for surveillance following 
curative- intent CRC resection, since it combines intraluminal 
 o
n
 June 19, 2020 at BVA. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319858 on 27 November 2019. Downloaded from 
210 Rutter MD, et al. Gut 2020;69:201–223. doi:10.1136/gutjnl-2019-319858
Guidelines
assessment for metachronous polyps and cancer with evaluation 
of the extracolonic structures for locoregional recurrence and 
remote metastases, thereby simplifying follow- up pathways and 
potentially reducing costs.
A systematic review and meta- analysis of cohort studies81 
showed that CTC was highly sensitive (95%, 18 of 19 cases 
detected) and 100% specific for anastomotic recurrence, as 
well as detecting 10 of 10 metachronous cancers. However, this 
article did not assess the diagnostic sensitivity of CTC for polyps 
or adenomas (as opposed to carcinoma).
Three single centre prospective cohort studies82–84 showed 
promising accuracy of CTC for polyps after prior CRC resec-
tion, the largest83 (550 patients) reporting a sensitivity of 81.8% 
for AN and a specificity of 93.1%. However, these studies were 
of variable quality, with incomplete84 or delayed83 comparison 
to reference standard tests such as colonoscopy for the presence/
absence of polyps.
A recent high- quality multicentre prospective cross- sectional 
study85 86 recruited 231 patients scheduled for 1 year colonic 
surveillance following curative- intent resection of CRC and 
conducted both CTC and same- day colonoscopy with segmental 
unblinding (ie, sequential revelation of the CTC result to the 
colonoscopist on a segment- by- segment basis, thereby providing 
an enhanced reference standard). CTC was only 44.0% sensi-
tive for 6 mm+polyps and 76.9% sensitive for 10 mm+polyps; 
the authors speculate this poor performance was due to colonic 
under- distension in patients with previous right hemicolectomy 
and thus no ileocaecal valve to permit optimal colonic disten-
sion. Although the negative predictive value was reasonable 
(85.8% for 6 mm+polyps and 98.5% for 10 mm+polyps), this 
may have been due to low prevalence rather than test accu-
racy. If 1000 patients underwent CTC instead of colonoscopic 
surveillance, although 922 colonoscopies would be avoided, 87 
patients would have 6 mm+polyps missed, and only 69 patients 
with 6 mm+polyps would be identified; 30 patients would 
have 10 mm+polyps identified, but 13 patients would have 
10 mm+polyps missed. Cost- effectiveness analysis of this risk- 
benefit trade- off has not yet been published.
We recommend that when post- polypectomy surveillance is 
indicated, the radiation risk of CTC is likely to be outweighed 
by its potential benefits.
GRADE of evidence: High 
Strength of recommendation: Strong
The precise radiation dose from CTC varies between scanners, 
but in two international surveys from 2008 and 2012 the average 
effective radiation dose was estimated at 9.1 mSv for symptom-
atic/diagnostic scans and 5.7 mSv for screening/follow- up scans 
in 2008,87 and 7.6 mSv (symptomatic) and 4.4 mSv (screening) in 
2012.88 This compares to average annual background radiation 
exposure of 2–3 mSv per annum in the UK. A 2012 single- centre 
report, using more modern CTC technology, which is now 
widely used in the UK, estimated doses to be around 2.5–3 mSv.89 
Therefore, a single CTC examination is likely to incur approx-
imately between 1 and 3 years’ worth of background radiation.
The risk of cancer induction associated with this level of 
radiation exposure is uncertain, but in one radiation modelling 
study90 the lifetime attributable risk (LAR) of cancer induc-
tion from a single scan at age 50 years was estimated to be 1 
in 1670, and a risk of 1 in 670 for a 5- yearly CTC screening 
strategy. The authors estimated the benefit:risk ratio (ie, CRCs 
prevented:other cancers induced by radiation) for such a 
screening strategy to be approximately 24–35:1 depending on 
the colorectal carcinogenesis model used. However, they did 
not directly model a surveillance (rather than primary screening) 
population, and radiation doses were assumed to be higher than 
outlined above, at 8 mSv per CTC. We found no published data 
specifically modelling the risks of repeated CTC at a variety of 
surveillance intervals.
The risk of inducing cancer due to radiation exposure decreases 
with age. In England, the average age of individuals having CTC 
is approximately 70 years (data from the Diagnostic Imaging 
Dataset - https:// did. hscic. gov. uk/; comparable data from other 
devolved nations are not available). The risk for a single 5 mSv 
scan at age 70 years is approximately 1 in 5000 (estimated 
via the National Cancer Institute Radiation Risk Assessment 
Tool,91 available at https:// irep. nci. nih. gov/ radrat). For repeated 
surveillance examinations, much will depend on the frequency 
such CTC surveillance is required; however, assuming 3- yearly 
repeated 5 mSv examinations starting at age 50 and ending at age 
70 years, the additional risk of malignancy is approximately 1 in 
525. As the inherent baseline risk of cancer is approximately 1 in 
3, this is a very small relative increase, and is likely outweighed 
by the potential benefits of preventing CRC in patients who have 
been identified as high- risk (by virtue of their need for colonic 
surveillance). The risk must also be weighed against the alterna-
tive—that is, adverse incidents arising from repeated colonos-
copic surveillance. Since radiation risks are greater in younger 
patients, in whom endoscopic perforation risks are smaller, 
and vice versa for older patients, the risk:benefit equation will 
vary according to patient factors including age, intensity of the 
surveillance programme and comorbidity.
Therefore, the radiation risk of cancer induction from CTC is 
very small and the risks are significantly outweighed by detection 
of cancer when colonic surveillance with CTC is indicated.
We do not recommend the use of faecal immunochemical 
testing (FIT) for surveillance after resection of premalignant 
colorectal polyps, as there is insufficient evidence.
GRADE of evidence: Low 
Strength of recommendation: Strong
Several studies report on the long- term performance of 
FIT- based population screening programmes for CRC, but 
evidence for surveillance after polypectomy is lacking in these 
studies. One study reports on participants recruited between 
January 2012 and December 2013 via the English BCSP.92 
Men and women aged 60–72 years, deemed at intermediate- 
risk following adenoma removal after a positive guaiac faecal 
occult blood test, were offered quantitative FIT at 1, 2 and 
3 years post- polypectomy. Participants testing positive with any 
FIT were referred for colonoscopy. Participants testing negative 
were offered colonoscopy at 3 years post- polypectomy (standard 
English BCSP surveillance). Of 8009 individuals invited, 5938 
(74%) consented and returned a Round 1 FIT. In this group, 
uptake of FIT in Rounds 2 and 3 was 97%. Programme sensi-
tivities of three FITs at 10 µg/g were 72% for CRC and 57% for 
AA. The use of FIT for surveillance could miss 30–40% of CRCs 
and 40–70% of AAs.
We do not recommend the use of colon capsule for surveil-
lance after resection of premalignant colorectal polyps, as there 
is insufficient evidence.
GRADE of evidence: Very low 
Strength of recommendation: Strong
A number of studies report on the diagnostic accuracy of 
colon capsule when compared with optical colonoscopy, but 
evidence for the use of capsule for surveillance after polypec-
tomy is lacking—apart from one recent study of 180 patients, of 
whom only 43% had a satisfactorily complete capsule assessment 
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and over half required subsequent lower GI endoscopy due to 
possible polyp identification.
surveillance evidence statements
There is some, but inconsistent, evidence that adenomas with 
high- grade dysplasia at index colonoscopy are associated with an 
increased risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Moderate
Thirteen studies reported evidence relating to risks at first 
surveillance associated with the presence of high- grade dysplasia 
at index colonoscopy. There were fairly consistent positive asso-
ciations of finding AA at surveillance, with generally low to 
moderate risk of bias. Five studies31 32 93–97 reported a statisti-
cally significantly increased odds of AA at first surveillance if 
high- grade dysplasia (HGD) was present at index colonoscopy. 
Atkin et al31 32 reported an incidence of AA of 19.06% (OR 1.44, 
95% CI 1.18 to 1.75), and Huang et al95 reported an incidence of 
27.7% (HR 1.61, 95% CI 1.07 to 2.42). ORs only were reported 
by Facciorusso et al96 97 and Fairley et al,94 respectively, as 4.25 
(95% CI 2.11 to 7.5) and 4.3 (95% CI 2.2 to 8.4), and Van 
Enckevort et al93 reported an HR of 1.73 (95% CI 1.13 to 2.64).
Five studies12 98–101 only reported statistical analyses on AN, 
with four reporting no significant association between HGD at 
index and risk of AN at first surveillance, and the fifth study 
(Cubiella et al100) reporting an OR of 0.7 (95% CI 0.5 to 0.98), 
consistent with reduced risk associated with HGD. Again, risk of 
bias was generally rated as moderate to low. Across these studies, 
where reported, the incidence ranged from 12.1%100 for AN up 
to 16% for AA and CRC 1.3%.12
The risk of CRC at surveillance was reported in three studies, 
all rated as having a low risk of bias,31 32 94 102 and again demon-
strated consistent statistically significant associations between 
HGD at index and CRC incidence, although the number of 
events was very small. One of these studies reported the inci-
dence of CRC as 3.1% (OR 2.09, 95% CI 1.29 to 3.37).31 32 102 
The two other studies reported an OR of 13.2 (95% CI 2.8 to 
62.1) for incidence of CRC,94 and an OR of 1.61 (95% CI 1.07 
to 2.42) for interval CRC.102
Only one study reported evidence for HGD and long- term 
CRC incidence,31 32 demonstrating a significant association with 
HGD at index colonoscopy (OR 1·85, 95% CI 1.34 to 2.55). 
Although this study was large and was rated as having a low risk 
of bias, the number of events was very small.
No studies reported evidence for HGD and long- term CRC 
mortality.
Analysis of English BCSP surveillance data (n=43 131 for AA; 
n=28 468 for CRC) showed HGD was not significantly associ-
ated with subsequent diagnosis of CRC on univariable analysis. 
Moreover, although HGD was weakly associated with AA at first 
surveillance, this was not significant on multivariable analysis 
(OR 1.08, 95% CI 0.994 to 1.172).103–105
There is consistent evidence that adenomas with tubulovillous 
or villous histology at index colonoscopy are associated with an 
increased risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Moderate
Sixteen studies reported evidence relating to risks at first 
surveillance associated with the presence of tubulovillous or 
villous histology at index colonoscopy. Overall, the evidence 
suggests that risk for AA at first surveillance was increased if 
tubulovillous or villous components (rather than tubular) were 
identified at index, with consistent statistically significant asso-
ciations reported across four studies31 32 94 95 106 rated as low to 
moderate risk of bias, and in one study107 rated as having a high 
risk of bias. Incidence of AA when tubulovillous components 
were identified at index was 17.5% (OR 1.93, 95% CI 1.59 to 
2.34) and 25.1% (OR 3.03, 95% CI 2.33 to 3.95) when villous 
components were identified.31 32
The incidence of AA on surveillance when tubulovillous 
and villous histology were reported at index colonoscopy was 
reported as 21.2% by Nusko et al.107 Incidence for tubulovil-
lous and villous histology combined was reported as 26.1% (HR 
2.57, 95% CI 1.24 to 5.32) in Huang et al,95 and Fairley et al94 
reported an OR for villous histology of 3.7 (95% CI 2.9, 4.7). 
Laiyemo et al106 presented risk ratios comparing AA with no AA 
at first surveillance and AA with no adenoma at first surveillance, 
reporting statistically significant risk ratios of 2.38 (95% CI 1.56 
to 3.64) and 2.25 (95% CI 1.49 to 3.39), respectively. A further 
study108 reported no significant association when the index 
tubulovillous adenoma was <10 mm (OR 0.63, 5% CI 0.36 
to 1.12), but the association was statistically significant when 
it was ≥10 mm (OR 2.11, 95% CI 1.40 to 3.19). Two further 
studies96 97 109 did not report statistically significant associations 
for villous components and incident AA.
When the outcome measure was detection of AN, at surveil-
lance, the findings were similar, with five studies rated as low to 
moderate risk of bias12 98–101 identified. Four of the five studies 
reported significant associations, showing increased risk for 
AN at first surveillance if tubulovillous or villous components 
(rather than tubular) were identified at index. Incidence of AN 
when villous components were identified at index was reported 
as 15.5% (OR 1.4, 95% CI 1.1 to 1.7)100 and 11.9%,99 while 
Van Heijningen et al101 reported an OR of 2.0 (95% CI 1.2 to 
3.2) with incidence of AA of 13% and CRC of 3.8%. Where 
findings were reported for tubulovillous and villous components 
combined, Martinez et al12 reported an OR of 1.28 (95% CI 
1.07 to 1.52) with incidence of AA of 16.8% and CRC of 0.9%. 
In the final study,98 although the HR indicated an increased risk 
(HR 1.29, 95% CI 0.92 to 1.81), it was not statistically signifi-
cant. A number of studies did not include data relating to the 
number of events.
The risk for CRC at first surveillance was reported in five 
studies rated as low risk of bias,31 32 94 102 108 110 with all five 
reporting statistically significant findings, showing that risk 
for CRC was increased at first surveillance if tubulovillous or 
villous histology (rather than tubular) was present at index. 
Atkin et al31 32 reported an incidence of CRC of 1.83% (OR 
1.76, 95% CI 1.00 to 3.09) if tubulovillous components were 
identified at index and 4.14% (OR 4.09, 95% CI 2.13 to 7.86) 
if villous components were identified. Fairley et al94 reported 
a statistically significant OR of 7.4 (95% CI 2.5 to 21.5) for 
the risk of CRC if villous components were present at index. 
The incidence of CRC was reported as 2.9% (HR 1.51, 95% CI 
1.02 to 2.23),110 and the odds for interval CRC was 1.38 (95% 
CI 1.03 to 1.85)102 if tubulovillous or villous components were 
present at index. Laish et al108 reported the incidence of CRC 
at first surveillance if small tubulovillous adenomas (TVA) were 
present at index as 1.5%, and as 1.3% for large TVA.
One study, rated as having a low risk of bias, presented evidence 
on long- term CRC incidence31 32 showing, in univariable anal-
yses, a statistically significant increased risk for long- term CRC 
(vs tubular) if tubulovillous components were present at index 
(HR 1.36, 95% CI 1.00 to 1.87) and if villous components were 
present (HR 1.65, 95% CI 1.03 to 2.64). There was no statisti-
cally significant increased risk for long- term CRC if tubulovil-
lous or villous histology was present at index in multivariable 
analysis. One other study on long- term CRC mortality111 112 
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reported tubulovillous or villous histology was a statistically 
significant risk factor for CRC (HR 1.30, 95% CI 1.13 to 1.50).
Overall, there was fairly consistent moderate to high quality 
evidence suggesting that tubulovillous or villous histology at 
index is associated with an increased risk for AA or AN and CRC 
at next surveillance. Findings were reported across a number 
of studies, and, although there is some uncertainly due to the 
lack of absolute values available in some studies, the evidence 
was consistent, with a number of large studies rated as having 
a low risk of bias. Evidence for long- term CRC incidence and 
mortality was limited, being presented in only one study for each 
outcome; however, each was a large- scale study rated as either 
low or moderate risk of bias.
Analysis of English BCSP surveillance data showed villous 
histology was not statistically significantly associated with 
subsequent CRC incidence at surveillance. However, it was 
statistically significant for AA at first surveillance on univari-
able analysis: OR 1.38 for TVA (95% CI 1.296 to 1.487), OR 
1.89 for villous adenoma (VA) (95% CI 1.654 to 2.170); and 
on multivariable analysis: OR 1 for tubular adenoma only, OR 
1.37 for TVA (95% CI 1.277 to 1.472), OR 1.69 for VA (95% CI 
1.475 to 1.952).103–105
There is consistent evidence that larger adenomas (of at least 
20 mm) at index colonoscopy are associated with an increased 
risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Moderate
There is some, but inconsistent, evidence that larger adenomas 
(of at least 10 mm) at index colonoscopy are associated with an 
increased risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Moderate
Fifteen studies reported evidence relating to polyp size and 
were rated as having a moderate to low risk of bias. Risk for AA 
at first surveillance was increased if the size of the adenoma at 
index was ≥20 mm; this association was statistically significant 
in three studies,31 32 95–97 in which the incidence of AA at surveil-
lance ranged from 21.4%31 32 to 81.1%.95
One study reporting the outcome AA,94 and three studies 
reporting the outcome AN12 98 101 at surveillance, found signifi-
cant associations if the size of the adenoma was between 10 mm 
and 20 mm at index. One study reported an OR of 3.6 (95% CI 
2.8 to 4.5),94 and one study reported a HR of 1.81 (95% CI 1.28 
to 2.55).98 No other associations relating to adenomas at smaller 
sizes were statistically significant for either AA or AN.
Two studies,31 32 94 rated as having a low risk of bias, reported 
on the outcome of CRC incidence at next surveillance. Risk for 
CRC at first surveillance was statistically significantly associated 
with size of the adenoma at index of ≥20 mm in one of these 
studies.31 32 The other reported an OR of 5.2 (95% CI 1.8 to 
15.1) for size of adenoma at index of ≥10 mm.94 One study on 
the outcome of interval CRC reported no statistically significant 
association when size of adenoma at index was ≥10 mm102; 
although the number of patients in this polyp category at index 
was small, the point estimate suggested an increased risk.
Only one study rated as low risk of bias presented evidence 
regarding long- term CRC incidence.31 32 Statistically significant 
associations were reported for adenomas 10–19 mm in size (inci-
dence 2.1%) and for those ≥20 mm in size (incidence 1.7%).
The GDG found no evidence regarding associations between 
polyp size at index colonoscopy and long- term CRC mortality.
Analysis of English BCSP surveillance data showed polyp size 
was not statistically significant for CRC detection on univari-
able analysis; however, it was statistically significant for AA yield 
at first surveillance on univariable analysis: OR 1 for largest 
adenoma of 10–14 mm; OR 1.28 for 20–29 mm (95% CI 1.171 
to 1.401); OR 1.57 for 30–39 mm (95% CI 1.369 to 1.804); OR 
2.10 for ≥40 mm (95% CI 1.817 to 2.431); and was statistically 
significant for AA at first surveillance on multivariable analysis: 
OR 1.38 for non- pedunculated adenoma of ≥10 mm compared 
with none (95% CI 1.288 to 1.483).103–105
There is consistent evidence that multiplicity of adenomas at 
index colonoscopy is associated with an increased risk of AA 
and AN at first surveillance. There is some, but inconsistent, 
evidence for an association with an increased risk of CRC at first 
surveillance.
GRADE of evidence: Moderate
Twenty- one studies, rated from low to high risk of bias, 
presented evidence on risk associated with number of adenomas 
at index. Results were not consistently statistically significant. 
Having two adenomas (compared with one) at index was statis-
tically significantly associated with increased risk of AA at next 
surveillance in two studies, in which the incidence of AA was 
18.3%31 32 and 6.1%.95 Three studies reported statistically signif-
icant increased risks of AA for ≥3 adenomas at index, compared 
with 1 or 2 adenomas,94 95 113 and one further study reported 
a significant increased risk for ≥3 vs 1 or 2 non- advanced 
adenomas at index or if multiple AAs were present at index.108 
Facciorusso et al96 97 reported a significantly increased risk with 
the presence of more than one AA at index (OR 3.22, 95% CI 
2.19 to 5.39) and Jang et al114 reported a statistically significant 
increase in the odds of AA at first surveillance with increasing 
number of adenomas at index. However, Atkin et al31 32 reported 
no significant association for three or four adenomas versus one 
adenoma, and three further studies reported no significant asso-
ciations for any comparisons.106 109 115
Six studies, rated as having low to moderate risk of bias, 
reported evidence for the outcome AN. Four studies, ranging in 
size from 1414 to 9167 patients, showed significantly increased 
risks for AN with increasing numbers of adenomas at index, 
although the comparisons made in the studies varied.12 100 101 116 
The other two studies did not find any associations between 
number of adenomas present at index and AN.99 117
Six studies, rated as having low to moderate risk of 
bias31 32 94 102 108 110 118 reported on the outcome CRC at next 
surveillance. Two of these found statistically significantly 
increased risks with increased numbers of adenomas at index94 118; 
this was seen for AA, but not non- advanced adenomas in one 
of the studies.118 Laish et al108 reported increasing incidence 
of CRC with increasing number of non- advanced adenomas 
at index (1–2 non- advanced adenomas, 1.1%; ≥3, 2.7%), and 
higher incidence in those with multiple AAs at index (3.7%). 
Three studies reported no statistically significant increased risk 
of CRC incidence31 32 110 and one study found no association 
with interval CRC,102 with increasing numbers of adenomas. 
One study, rated as having a low risk of bias,31 32 found no statis-
tically significant association with long- term CRC incidence.
One further large- scale study111 112 reported a statistically 
significant increased risk of CRC mortality if more than one 
adenoma was present at index (HR 1.30, 95% CI 1.10 to 1.55).
Analysis of English BCSP surveillance data showed that multi-
plicity was statistically significant for CRC on multivariable anal-
ysis (compared with one adenoma, HR 2.45 for 6–9 adenomas 
(95% CI 1.523 to 3.952), and HR 3.58 for ≥10 adenomas 
(95% CI 1.879 to 6.821)). Adenoma multiplicity was also statis-
tically significant for AA at first surveillance on univariable anal-
ysis (compared with one adenoma, OR 1.62 for two adenomas 
(95% CI 1.469 to 1.798); OR 1.61 for three adenomas (95% CI 
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1.457 to 1.783); OR 2.02 for four adenomas (95% CI 1.806 to 
2.262); OR 2.38 for five adenomas (95% CI 2.113 to 2.696); 
OR 2.75 for 6–9 adenomas (95% CI 2.475 to 3.076); and OR 
3.82 for ≥10 adenomas (95% CI 3.278 to 4.473)). It was also 
statistically significant for AA at first surveillance on multivari-
able analysis: OR 1.56 for two adenomas (95% CI 1.407 to 
1.736); OR 1.58 for three adenomas (95% CI 1.424 to 1.753); 
OR 1.90 for four adenomas (95% CI 1.692 to 2.136); OR 2.23 
for five adenomas (95% CI 1.973 to 2.538); OR 2.47 for 6–9 
adenomas (95% CI 2.208 to 2.773); and OR 3.03 for ≥10 
adenomas (95% CI 2.578 to 3.570).103–105
There is some, but inconsistent, evidence that proximal 
adenomas at index colonoscopy are associated with an increased 
risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Low
Twelve studies, rated as having low to high risk of bias, presented 
evidence on the risk associated with the presence of proximal 
adenoma at index. The findings were inconsistent. Seven studies, 
ranging in size from 47 to 11 944 patients, presented evidence 
relating to the risk of AA at first surveillance.31 32 95 106 109 113–115 
Only one of these106 reported a statistically significant increased 
risk for proximal adenomas at index versus either non- advanced 
adenoma or no adenoma (AA vs non- AA at first surveillance: RR 
1.58, 95% CI 1.11 to 2.25; AA vs no adenoma at first surveil-
lance: RR 1.84, 95% CI 1.31 to 2.59).
All three studies which presented data on the outcome AN 
reported statistically significant increased risks associated with 
proximal adenomas at index colonoscopy.12 99 101
There was no evidence for a statistically significant association 
with proximal adenomas and CRC incidence at next surveillance 
in two studies,31 32 118 but one of these31 32 reported a statisti-
cally significant association with risk for long- term CRC (HR 
1.76, 95% CI 1.30 to 2.38). One further large- scale study111 112 
reported no association between proximal adenomas at index 
and CRC mortality.
Analysis of English BCSP surveillance data showed presence 
of a proximal adenoma was statistically significant for CRC on 
univariable analysis (HR 1.53, 95% CI 1.159 to 2.027) but not 
on multivariable analysis. It was statistically significant for AA at 
first surveillance on univariable analysis (OR 1.67, 95% CI 1.574 
to 1.782), but not significant on multivariable analysis.103–105
There is no consistent evidence that adenomas with sessile or 
flat morphology at index colonoscopy are associated with an 
increased risk of AA, AN and CRC at first surveillance.
GRADE of evidence: Low
Four studies,95–97 100 113 three of which were rated as low risk 
of bias, and one as high risk, presented evidence on the risk 
associated with adenoma morphology at index. Of three studies 
which presented evidence on the risks for AA,95–97 113 the largest 
of which included 1356 patients, only one reported a statisti-
cally significant increased risk in patients with sessile (OR 1.96, 
95% CI 1.12 to 2.43) or non- polypoid adenomas (OR 2.43, 
95% CI 1.14 to 3.26) at index, relative to those with pedun-
culated adenomas.96 97 The other two studies reported non- 
significantly increased risk.
One study presented evidence relating to the outcome AN100 
and found no statistically significant findings relating to adenoma 
morphology at index.
No evidence relating to CRC at the next surveillance, long- 
term CRC incidence, or long- term CRC mortality was identified.
There is some, but inconsistent, evidence that male sex is 
associated with an increased risk of AA, AN and CRC at first 
surveillance.
GRADE of evidence: Very low
Twenty studies, with generally a low risk of bias, presented 
evidence on the association between male sex and outcomes at 
first surveillance. Eleven studies presented evidence relating to 
AA31 32 95–97 102 106 109 114 115 119–122; of these, four studies presented 
evidence showing a statistically significant increased risk of AA 
at first surveillance if the patient was male.95 102 114 122
Five studies presented evidence on the outcome AN,12 98 100 116 117 
with one study12 reporting a statistically significant increased 
risk of AN at first surveillance in men (OR 1.40, 95% CI 1.19 to 
1.69), with detection rates of 11.7% for AA and 0.8% for CRC.
Four studies presented evidence on detection rates of CRC at 
first surveillance, with only one study110 reporting male sex as 
a statistically significant risk factor (HR 1.69, 95% CI 1.26 to 
2.27).
One study reported no association between male sex and 
long- term risk of CRC among 11 944 patients deemed to be at 
intermediate- risk according to the 2002 adenoma surveillance 
guidelines,31 32 while a further study reported no association 
between male sex and long- term CRC mortality.111 112
Analysis of English BCSP surveillance data showed that sex 
was not associated with CRC on univariable or multivariable 
analysis. However, men had a higher risk of AA at first surveil-
lance in both univariable (OR 1.30, 95% CI 1.213 to 1.399) and 
multivariable analysis (OR 1.13, 95% CI 1.049 to 1.223).103–105
There is consistent evidence that a family history of CRC 
(which falls short of warranting family history surveillance in its 
own right) is not associated with an increased risk of AA, AN or 
CRC at first surveillance
GRADE of evidence: Moderate
We assessed the published evidence of the diagnostic yield of 
post- polypectomy surveillance in those with a family history of 
CRC. This evidence search did not include patients undergoing 
surveillance because of their family history per se, which has been 
reviewed for the hereditary CRC guidelines (in press). Seven 
studies, rated as moderate to low risk of bias,12 98 106 114 117 118 122 
reported evidence on the risks associated with a family history of 
CRC. Two studies reported on the outcome AA,114 122 and three 
on the outcome AN.12 98 117 There was no statistically significant 
increased risk of either AA or AN at first surveillance for patients 
with a family history of CRC.
One study reported on the incidence of CRC at first surveil-
lance118 and again there was no evidence for increased risk 
associated with a family history of CRC. Cottett et al118 
presented evidence separately for those with AA at index, 
and for those with non- AA at index. In those with an AA at 
index both those with a family history (standardised incidence 
ratio (SIR) 3.76, 95% CI 1.51 to 7.75) and those without (SIR 
2.10, 95% CI 1.54 to 2.81) were at statistically significantly 
increased risk for CRC at first surveillance. A formal statistical 
test for difference between those with or without family history 
was not performed. In the non- AA group neither those with or 
without a family history of CRC were at increased risk of CRC, 
although as for the analysis above a formal statistical test for 
difference between those with or without family history was 
not performed.
Only one study reported on the long- term incidence of 
CRC,106 reporting that of new CRC cases diagnosed during 
follow- up, 44% (4/9) had a family history of CRC; however, no 
statistical analyses were presented.
No evidence on family history, surveillance and long- term 
CRC mortality was identified.
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There is consistent evidence that younger age is associated with 
a decreased risk of AA, AN and CRC at first surveillance, and 
also a decreased risk of long- term CRC incidence and mortality.
GRADE of evidence: Moderate
Twenty studies, generally rated as low risk of 
bias12 31 32 93 95 98 100 102 106 109–118 120–123 presented evidence on 
the risks of neoplasia associated with increasing age, and demon-
strated that there is relatively consistent evidence suggesting that 
younger people are at lower risk.
Ten studies31 32 93 95 106 109 113–115 120–122 reported on AA. Studies 
used a younger age range as the reference (eg, <55 years) and 
reported risks for a range of different older age groups, or 
presented the findings as the risk associated with continuous 
increasing age. Two studies reported increased risks for AA at 
first surveillance associated with older age but these were not 
statistically significant.109 114 In three of the remaining eight 
studies, compared with a younger age group, AA incidence at 
first surveillance was statistically significantly increased for 
those aged from 55 years to those over 80 years, with incidence 
ranging from 10.9% for the 50–60 year age group95 to 22.75% 
in the 80 years or older age group.31 32 Five further studies with 
increasing age presented as a continuous variable presented 
evidence showing statistically significant increased risks for AA 
at first surveillance93 106 115 120–122 with ORs ranging from 1.02 
(95% CI 1.01 to 1.04)122 to 1.47 (95% CI 1.16 to 1.87).120 121
Six studies reported on AN.12 98 100 116 117 123 Three studies 
presented evidence per age group relative to the younger age 
group. Martinez et al12 reported statistically significant increased 
risks for AN across three age groups (61–71; 80+years) compared 
with the younger age group (50–59 years), with incidence of 
AA at first surveillance as 12.2%, 14.5%, and 17.7%, respec-
tively. Furthermore, Martinez et al also presented evidence on 
the younger than 40 age group, and the 40–49 age group rela-
tive to the 50–59 age group. For both age groups the ORs and 
95% CIs were below 1, suggesting that younger age has a protec-
tive effect. Park et al98 reported only the 70 year or older age 
group had statistically significantly increased risk for AN (HR 
2.56, 95% CI 1.43 to 4.59), while for the 50–70 year age group 
there was no statistically significant association. The association 
reported by Cubiella et al100 for the 60–69 year age group rela-
tive to the 50–59 year age group was not statistically significant. 
Two studies reported statistically significant increased risks for 
AN with increasing age: with age as a continuous variable the 
HR was 1.02 (95% CI 1.01 to 1.03)117 and with age increasing 
with yearly increments the OR was 1.04 (95% CI 1.01 to 
1.07).116 Kim et al found no significant difference in AN on 
surveillance when comparing 20–29 year- olds with 40–44 and 
45–49 year- olds.123
Four studies31 32 102 110 118 reported evidence on incidence of 
CRC at first surveillance. All four studies reported statistically 
significant associations between risk of CRC and increasing age, 
although it should be noted that there are a small number of 
events across each age group. All four studies used a younger 
age range as the reference (eg, <55 years; 50–60 years) and 
reported risks for a range of different older age groups. Rela-
tive to patients younger than 55 years, Atkin et al31 32 reported 
only those 75 years or older had statistically significant increased 
risk for CRC at first surveillance, with incidence reported as 
5.08% and 5.58%, respectively. Coleman et al110 reported, 
relative to the under 50 year group, significantly increased risks 
for CRC for the 60–69 group, the 70–79 group, and the 80 
years or older group, with incidence of CRC at first surveillance 
reported as 2.7% and 3.7–5.9% respectively, whereas there was 
no significantly increased risk in the 50–59 age group. Huang et 
al102 reported on interval CRC showing a statistically significant 
increased risk for the 60 years or older age group (OR 1.34, 
95% CI 1.08 to 1.92) relative to the under 50 year age group, 
but this comparison was not significant for the 50–60 year age 
group. Cottet et al118 reported on the risk of CRC at first surveil-
lance associated with increasing age groups for those with AA 
and those with non- AA at index separately. For each of the age 
groups the SIR was statistically significant for those with AA at 
index (<60 years: SIR 3.65, 95% CI 1.88 to 6.37; 60–79 years: 
SIR 1.75, 95% CI 1.18 to 2.50; ≥80 years: SIR 3.32, 95% CI 
1.66 to 5.95). However, there was no increased risk associated 
with any of the three age groups when patients had a non- AA 
at index.
Long- term CRC incidence was reported on in one study31 32 
reporting statistically significant increased risk in older patients, 
and two studies111 112 reported a higher long- term CRC mortality 
in older patients.
There is consistent evidence that increasing age is associated 
with an increased risk of AA, AN and CRC at first surveillance, 
and of long- term CRC incidence and mortality.
GRADE of evidence: Moderate
Studies assessing age as a prognostic risk factor using a 
younger age group as a reference are outlined in the previous 
section. Studies of people older than 75 years compared with 
younger cohorts demonstrated a similar pattern, with statisti-
cally significant increased risks in older cohorts compared with 
younger reference cohorts (<55 years), for AA31 32 and AN12 
at first surveillance, for CRC incidence at first surveillance in 
two studies,31 32 110 yet only for those with an AA at index in a 
further study,118 for long- term CRC incidence31 32 and for long- 
term CRC mortality.111 112
Analysis of BCSP surveillance patients in England demon-
strated a statistically significant risk for CRC in older people 
on multivariable analysis: HR 1 for age <65 at screening, HR 
2.08 for age >69 at screening (95% CI 1.299 to 3.350), and a 
statistically significant increased risk for AA at first surveillance 
on univariable but not on multivariable analysis.103–105
There is no consistent evidence that current smoking status 
is associated with an increased risk of AA, AN or CRC at first 
surveillance.
GRADE of evidence: Low
Five studies, rated as having low to moderate risk of 
bias,12 98 115 117 122 presented evidence relating smoking status to 
the risks of neoplasia at first surveillance. Two studies presented 
evidence on the association between smoking and AA115 122 
and three studies presented evidence on smoking and AN at 
first surveillance12 98 117; none of these studies found significant 
associations. No studies have examined the association between 
smoking status and detection rates of CRC at first surveillance, 
long- term CRC incidence, or long- term CRC mortality.
Analysis of English BCSP surveillance data showed that 
smoking status at index colonoscopy was not statistically signifi-
cantly associated with subsequent CRC at first surveillance in 
univariable or multivariable analysis. However, it was statistically 
significant for AA at first surveillance on univariable analysis: 
compared with never smokers, OR 1.12 for ex- smoker (95% CI 
1.048 to 1.201), OR 1.33 for current smoker (95% CI 1.225 
to 1.462); and on multivariable analysis: OR 1.16 for current 
smoker versus never/ex- smoker (95% CI 1.064 to 1.264).103–105
There is no consistent evidence that high BMI is associated 
with an increased risk of AA, AN or CRC at first surveillance.
GRADE of evidence: Low
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Seven studies, rated as having a low to moderate risk of bias, 
examined BMI in relation to AA, AN or CRC at first surveil-
lance.12 98 106 114 115 117 122 Four studies examined the associa-
tion between BMI and AA at first surveillance.106 114 115 122 One 
study106 reported that patients with AA at index colonoscopy 
together with a high BMI had an increased risk of AA at first 
surveillance (RR 1.62, 95% CI 1.01 to 2.57). The remaining 
three studies found no associations between BMI and AA at first 
surveillance.114 115 122 Three studies examined the association 
between BMI and AN at first surveillance12 98 117; none of these 
studies found an association. No studies have examined BMI and 
detection rates of CRC at first surveillance, long- term CRC inci-
dence or long- term CRC mortality.
Analysis of English BCSP surveillance data showed high BMI 
at index colonoscopy was not associated with either CRC or AA 
at first surveillance on univariable or multivariable analysis.103–105
There is consistent evidence that inadequate bowel prepara-
tion at index colonoscopy is associated with an increased risk of 
AA, AN and CRC at first surveillance.
GRADE of evidence: Low
Five studies, ranging from low to high risk of bias, reported 
on the risks associated with different levels of bowel preparation 
quality.31 32 96 97 100 101 114 Three studies reported evidence on the 
risks for AA at first surveillance.31 32 96 114 Relative to excellent 
or good bowel preparation, there were statistically significant 
associations between poor bowel preparation and the risk for AA 
in two studies (Atkin et al31 32: OR 1.54, 95% CI 1.04 to 2.28; 
Jang et al114: OR 2.21, 95% CI 1.24 to 4.66). There were no 
statistically significant associations between adequate, moderate 
or satisfactory bowel preparation (relative to excellent) and the 
risk for AA.
Two studies reported evidence on the risks for AN at first 
surveillance,100 101 with only one101 reporting a statistically 
significant increased risk for AN associated with insufficient 
bowel preparation relative to good bowel preparation with 
an incidence of AA of 17.7% and CRC of 2.2%. There was 
no increased risk when bowel preparation was reported as 
moderate in the same study, and also when bowel preparation 
was reported as adequate (relative to inadequate) in a second 
study.100
One study31 32 reported on incidence of CRC at first surveil-
lance and presented similar findings in that there was only 
statistically significantly increased risk for CRC if bowel prepa-
ration was poor (OR 3.80, 95% CI 1.79 to 8.05) and not if it 
was satisfactory. The same study31 32 reported on long- term 
CRC incidence and again the associations were only statistically 
significant for poor bowel preparation (HR 2.09, 95% CI 1.19 
to 3.67) and not for satisfactory bowel preparation.
No studies were identified which presented evidence on bowel 
preparation quality and long- term CRC mortality.
There is consistent evidence that an incomplete index colo-
noscopy is associated with an increased risk of AA, AN and CRC 
at first surveillance.
GRADE of evidence: Low
Three studies, ranging from low to high risk of bias, presented 
evidence on the risks associated with completeness of colonos-
copy.31 32 100 101 Only one study31 32 reported on the risks for AA 
at first surveillance associated with incomplete colonoscopy at 
index, reporting a statistically significant increased risk for AA 
(OR 1.92, 95% CI 1.58 to 2.33).
Two studies100 101 reported on the risk for AN at first surveil-
lance and found no statistically significant association between 
incomplete colonoscopy and AN.
One study31 32 presented evidence on the risk for CRC at first 
surveillance and found an increased risk if colonoscopy was 
incomplete at index (OR 4.28, 95% CI 2.61 to 7.03); the same 
study31 32 presented evidence on long- term CRC incidence, simi-
larly finding an increased risk if colonoscopy was incomplete at 
index (HR 1.80, 95% CI 1.34 to 2.41).
No studies on colonoscopy completeness and long- term CRC 
mortality were identified.
Analysis of English BCSP surveillance data showed that a 
combination of either poor bowel preparation or incomplete 
colonoscopy to the caecum was not associated with CRC at 
first surveillance, but it was associated with AA in univariable 
(OR 1.30, 95% CI 1.098 to 1.553) and multivariable analyses 
(compared with complete colonoscopy with good or adequate 
prep, OR 1.46 for either poor prep or incomplete colonoscopy 
at screening, 95% CI 1.220 to 1.754).103–105
There is evidence to suggest that advanced serrated polyps 
are risk equivalent to AAs for future CRC risk, and surveillance 
should be as for AAs
GRADE of evidence: Low
Colonoscopic surveillance is predicated on the increased risk 
of CRC following adenoma removal; however, another major 
pathway to colorectal cancer, the “serrated pathway”, accounts 
for 15–30% of colorectal cancer and has serrated polyps as cancer 
precursors. The BSG position statement on serrated polyps in 
the colorectum recommended one- off surveillance colonoscopy 
at 3 years for patients with an advanced serrated polyp, defined 
as a sessile serrated lesion (SSL) ≥10 mm, SSL with dysplasia and 
traditional serrated adenomas.6 No prospective data to validate 
this recommendation exist; however, evidence strongly suggests 
that future CRC risk is increased in people with advanced 
serrated polyps to a level similar to that post adenoma detection. 
In a post- hoc analysis of the Norwegian flexible sigmoidoscopic 
screening study (NORCCAP), large (≥10 mm) serrated lesions 
were associated with the same future colorectal cancer risk as 
AAs (HR 4.2 vs 3.3, respectively).124 A recent larger study using 
three US cohorts combined with 122 899 patients showed a 
similar result with a significantly higher risk of CRC after resec-
tion of an AA or a large (≥10 mm) serrated polyp with hazard 
ratios of 4.07 and 3.35, respectively.125
In a large Danish cohort which re- analysed pathological 
samples using modern definitions of serrated polyps, serrated 
lesions alone were risk equivalent to adenomas alone for future 
cancer risk without considering size (adjusted OR 3.4 vs 2.5, 
respectively).126 Traditional serrated adenomas and SSL with 
dysplasia had a significantly higher risk of future CRC (adjusted 
OR 4.8 and 4.8, respectively).
There is evidence to suggest that the future CRC risk may 
be additive between serrated and adenomatous polyps and their 
numbers should be summated when determining surveillance 
intervals
GRADE of evidence: Low
There has been recent data on the future risk when adenomas 
and serrated lesions are found together. The risk of finding an 
AA at surveillance when an AA and serrated lesion were found 
together was fourfold higher than when an AA alone was the 
index lesion, suggesting that the risk may be more than addi-
tive between serrated and adenomatous lesions, with an OR for 
future risk with synchronous AAs and serrated lesions at index 
exam of 16.04 (95% CI 6.95 to 37) compared with an OR of 
3.86 (95% CI 2.77 to 5.39) for AAs alone.127 A further similar 
study from Korea also suggests additive risk between adenomas 
and SSLs, with the risk of AN at 3 years follow- up for adenoma 
 o
n
 June 19, 2020 at BVA. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319858 on 27 November 2019. Downloaded from 
216 Rutter MD, et al. Gut 2020;69:201–223. doi:10.1136/gutjnl-2019-319858
Guidelines
with synchronous serrated polyp being 17.9% versus 10.7% for 
adenoma alone (p<0.001). Audit data from an Australian CRC 
surveillance programme with 2157 patients followed up for a 
median of 50 months found additive risk of AN when serrated 
lesions and adenomas were found together (high- risk adenoma: 
HR 2.04, 95% CI 1.70 to 2.45; high- risk SSP + adenoma: HR 
3.20, 95% CI 1.31 to 7.82; low- risk SSP + adenoma: HR 2.20, 
95% CI 1.03 to 4.68).128 Older data from when serrated lesions 
were less recognised both endoscopically and pathologically 
(1994–1997) is supportive, but less definitive.129
There is evidence to suggest that serrated polyps <10 mm in 
size, except for rectal hyperplastic polyps, are risk equivalent to 
adenomas <10 mm in size for future CRC risk, and surveillance 
should be as for adenomas <10 mm in size.
GRADE of evidence: Low
The BSG position statement on serrated polyps in the 
colorectum recommended no surveillance for patients with one 
or more serrated lesions <10 mm in size who do not meet the 
criteria for serrated polyposis syndrome.6 No prospective data 
to validate this recommendation exist. In a US cohort from 
1994 to 1997 a proximal serrated polyp alone was associated 
with an increased risk of any adenoma during surveillance (OR 
3.14, 95% CI 1.59 to 6.20), but not AN (OR 2.09, 95% CI 
0.44 to 9.87)129; however, this cohort included approximately 
10% of serrated polyps ≥10 mm in size (25/248 proximal non- 
dysplastic serrated polyps). A US pathology based case–control 
study suggested that the rate of CRC was significantly higher in 
SSLs than in patients with adenomas or hyperplastic polyps over 
13 years follow- up (12.5% vs 1.8% vs 1.8%, respectively).130 
All serrated lesions with subsequent cancer were <10 mm in 
size; however, some serrated polyposis syndrome patients and 
patients with TSA were included, and it is not clear whether SSLs 
were resected comprehensively rather than biopsied.
No prospective data exist for the risk with multiple non- 
advanced serrated lesions; however, multiple serrated lesions 
are associated with synchronous AN (OR 4.86), though this 
may reflect the inclusion of some larger lesions. Given that 
non- advanced serrated lesions appear risk equivalent to non- 
advanced adenomas, their surveillance should be equivalent. 
Multiple studies suggest diminutive hyperplastic rectal polyps 
do not significantly increase risk of future CRC, therefore need 
not be resected.6
There is no consistent evidence to suggest that a surveillance 
interval of less than 3 years, when compared to 3 years, reduces 
CRC incidence or mortality
GRADE of evidence: Low
One study presented evidence directly comparing an interval 
of 3 years to less than 3 years. Atkin et al31 32 made comparisons 
to an interval of less than 18 months to 3 years, and showed that 
although there was an association with AA it was not statistically 
significant (3 years: OR 1.06, 95% CI 0.83 to 1.34).
Two studies31 32 119 reported non- significant associations 
between risk for AA and increasing interval between index and 
first surveillance. Atkin et al31 32 reported a non- significant but 
positive association, for the per year increase in risk for AA 
(univariable: OR 1.04, 95% CI 0.99 to 1.09; multivariable, OR 
1.03, 95% CI 0.98 to 1.09). Again, when comparing the interval 
of less than 18 months to each time interval, there was no statis-
tically significant association (2 years: OR 1.05, 95% CI 0.83 to 
1.33; 3 years: OR 1.06, 95% CI 0.83 to 1.34; 4 years: OR 1.10, 
95% CI 0.78 to 1.55; 5 years: OR 1.24, 95% CI 0.81 to 1.91; 6 
years: OR 0.90, 95% CI 0.51 to 1.61) until the comparison with 
6.5 years or more where the unadjusted odds were 1.94 (95% CI 
1.26 to 2.98), although this association did not remain signifi-
cant when adjusted for covariates.
Two studies reported on CRC incidence at next surveil-
lance,31 32 131 132 although only Atkin et al presented statistical 
analyses which showed that a longer interval was significantly 
associated with increased odds of CRC at first surveillance after 
multivariable adjustment (per year increase in interval OR 1.21, 
95% CI 1.08 to 1.37; p=0.0040). When comparing the interval 
between index and first surveillance, relative to an interval of 
less than 18 months, the odds of finding CRC at 2, 3 or 5 years 
was not statistically significant.
There was no evidence relating to surveillance interval and 
long- term CRC incidence and long- term CRC mortality.
There is insufficient evidence to determine whether a surveil-
lance interval of 3 years is superior to a longer interval, in terms 
of CRC incidence and mortality
GRADE of evidence: Low
Three studies reported on a comparison of 3 or 4 years or 
less compared with a longer interval. Pinsky et al119 reported no 
significant association for AA when they compared incidence at 
first surveillance of 4 years or less to incidence after an interval 
of more than 4 years. They showed that incidence of AA was 
9.6% when surveillance was performed no more than 4 years 
after index, and incidence of AA was 8% when surveillance was 
performed more than 4 years after index, with the associated 
odds of 0.86 (95% CI 0.6 to 1.2).
Chung et al133 reported on incidence of AA for the interval 
between index and first surveillance of less than 3 years 
compared with 3–5 years, for low- risk (7.1% vs 2.2%) and high- 
risk groups (10.1% vs 8.7%), but did not present statistical anal-
yses. Contrary to these findings, one study115 reported that an 
interval between index and first surveillance of 3 or more years 
was an independent risk factor for AA, reporting an adjusted 
OR of 2.97 (95% CI 1.11 to 7.93, p=0.030), but there was no 
statistically significant association when the interval was 5 years 
or more (OR 2.30, 95% CI 0.80 to 6.67; p=0.124.) One study 
only looked at AN100 and showed no significant association 
when comparing first surveillance at less than 3 years (14.4%, 
95% CI 12.6 to 16.2) to 3 or more years (13.3%, 95% CI 11.8 
to 14.7), with an associated OR of 1.0 (95% CI 0.8 to 1.2).
Two studies31 32 119 reported non- significant associations 
between risk for AA and increasing interval between index and 
first surveillance, and two studies reported on CRC incidence at 
next surveillance31 32 131 132 as described in the previous section.
There was no evidence relating to long- term CRC incidence 
and long- term CRC mortality.
There is insufficient evidence to determine who may benefit 
from a second surveillance procedure.
GRADE of evidence: Low
Two publications relating to one large study with a low risk of 
bias provide relevant evidence.31 32 The study reported findings 
regarding associations with prognostic factors at first surveillance 
and outcomes at second surveillance. Although some statistically 
significant associations between risk of AA or CRC at second 
surveillance and prognostic factors identified at first surveillance 
(no adenoma as reference) were reported, for some prognostic 
factors the number of patients was small, and the reported asso-
ciations were not statistically significant.
There was modest increased risk for AA at second surveil-
lance among those with HGD at first surveillance colonoscopy 
(OR 1.19, 95% CI 0.48 to 2.74),31 32 although this was not 
statistically significant. The number of patients with HGD at 
first surveillance was small. A greater number of patients had 
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low- grade dysplasia and there was a statistically significant asso-
ciation of low- grade dysplasia and AA at second surveillance 
(OR 1.70, 95% CI 1.19 to 2.43). There were no CRC events at 
second surveillance for patients with HGD.
Risk for AA at second surveillance was increased if tubulovil-
lous (OR 1.73, 95% CI 1.01 to 2.93) or villous components (OR 
2.23, 95% CI 1.09 to 4.54) were identified at first surveillance. 
There were no CRC events at second surveillance for patients 
with tubulovillous components. For villous components, there 
were few CRC cases and thus wide 95% CIs (OR 2.57, 95% CI 
0.31 to 21.70).31 32
Risk for AA at second surveillance was statistically signifi-
cantly increased if the size of the adenoma at first surveillance 
was ≥20 mm (OR 3.12, 95% CI 1.69 to 5.75). For adenomas of 
a smaller size the magnitude of the ORs suggests an increased 
CRC risk; however, the result was not statistically significant. 
There were no CRC events at second surveillance for patients 
with adenomas >10 mm. For patients with adenomas <10 mm 
there was an increased risk of CRC; however, the result was not 
statistically significant (OR 1.34, 95% CI 0.33 to 5.37).31 32
Risk for AA at second surveillance was statistically signifi-
cantly increased if the number of adenomas at first surveillance 
was two (OR 2.57, 95% CI 1.50 to 4.39), although there was 
no statistically significant increased risk for AA if patients had 
one, three, four or five (or more) adenomas at first surveil-
lance. There was no statistically significant association for any 
number of adenomas at first surveillance and risk of CRC at 
second surveillance.31 32 The number of events in each category 
was small.
Risk for AA at second surveillance was increased if an 
adenoma or polyp was identified at a proximal location at first 
surveillance (OR 1.87, 95% CI 1.25 to 2.82). There was no such 
association for CRC.31 32
There was no statistically significant association between male 
sex at first surveillance colonoscopy and risk for AA and CRC at 
second surveillance.31 32
There were no statistically significant associations between 
older age at first surveillance colonoscopy and risk for AA and 
CRC at second surveillance, although the general trend was for 
increased risk in most age groups compared with the reference 
category (<55 years).31 32
There is little evidence for an association between bowel prepa-
ration quality at first surveillance (reference excellent or good) 
and the risk of AA or CRC at second surveillance. There was 
only one statistically significant association reported showing the 
risk for AA was increased if bowel preparation quality was satis-
factory (OR 2.66, 95% CI 1.53 to 4.60); all other associations 
were not statistically significant for AA or CRC incidence.31 32
There was no evidence for a statistically significant association 
between the risk of AA at second surveillance and completeness 
of the colonoscopy at first surveillance (reference complete colo-
noscopy); however, there was a significant association between 
the risk of CRC at second surveillance where the colonoscopy at 
first surveillance was reported as incomplete (OR 5.72, 95% CI 
1.27 to 25.87).31 32
There was no evidence presented on the following prognostic 
factors for second surveillance: adenoma morphology, family 
history of CRC, smoking status, BMI, high quality colonosco-
pist, and high- adenoma- detecting technologies. There was no 
evidence for second surveillance and long- term CRC incidence 
or CRC mortality reported in this study.
There is insufficient evidence to determine the optimal interval 
between first and second surveillance.
GRADE of evidence: Low
Two studies examined the interval between first and second 
surveillance.31 32 134 Atkin et al demonstrated statistically signif-
icant increased odds for risk of AN per year increase (OR 1.11 
95% CI 1 to 1.24). In multivariable models for AN, using an 
interval of less than 18 months as referent, a 2 year interval was 
not statistically significant, but a 3 year (OR 2.02, 95% CI 1.19 
to 3.42), 4 year (OR 2.45, 95% CI 1.20 to 5.00), and more than 
6.5 year (OR 5.95, 95% CI 2.15 to 16.46) interval was signifi-
cant (an interval of 5 or 6 years was not significant). Miller et al 
(rated as having a moderate risk of bias) did not find an associ-
ation between risk for AA and interval between first and second 
surveillance when the interval was 3 or more years, compared 
with an interval of less than 3 years.134 There was no evidence 
for interval between first and second surveillance and long- term 
CRC incidence or CRC mortality.
There is no consistent evidence from surveillance studies 
to determine at what age, or at what life- expectancy, surveil-
lance can be stopped without increasing the risk of future CRC 
development.
GRADE of evidence: Very low
There is evidence that the risk of colonoscopy in a healthy 
patient is low, but that colonoscopy risks increase with comor-
bidity and advanced age.
GRADE of evidence: Moderate
Colonoscopy is an invasive procedure, and as such carries a 
risk. Complications may be GI (procedure- specific, for example, 
perforation or post- polypectomy bleeding) or non- GI (for 
example, renal impairment due to bowel preparation, cardiovas-
cular or cerebrovascular). While these risks are in general very 
low, they need to be weighed against the potential benefit of 
post- polypectomy surveillance colonoscopy.
The risk of either perforation or bleeding is small with 
diagnostic colonoscopy but increases when polypectomy is 
performed. The BSG audit demonstrated an overall perforation 
rate of 0.04%.135 Diagnostic perforation rates of 0–0.2% are 
reported,136–138 the English BCSP figure being 0.03%.138 Polyp-
ectomy perforation rates of 0.06–0.65% are reported,139–143 the 
English BCSP polypectomy procedure perforation rate being 
0.09%.138 Post- polypectomy bleeding (PPB) rates of 0.0.8–6.1% 
for polypectomies are reported,136 144 the English BCSP PPB rate 
(requiring transfusion) being at the lower end of this range at 
0.08%.138
Colonoscopy complication rates are higher in non- screening 
populations, probably due to both patient factors and colonos-
copist expertise.145
Colonoscopy risks also increase in older people and in 
people with comorbidity.146–149 Warren et al reported that risk 
for adverse events among persons undergoing colonoscopy 
increased with age and is significantly higher in patients 80 years 
or older compared with those 66 to 69 years. Relative to people 
aged 66 to 69 years, the adjusted predictive risk for adverse GI 
events was significantly higher for patients aged 80 years or 
older (risk per 1000 procedures in persons 80 to 84 years of 
age vs those 66 to 69 years of age: 8.8 (95% CI 6.9 to 10.7) vs 
5.0 (95% CI 3.8 to 6.2) for serious GI events and 15.9 (95% CI 
13.5 to 18.3) vs 6.9 (95% CI 5.6 to 8.2) for other GI events). 
Persons in the colonoscopy group were significantly more likely 
than their age- equivalent matched group to have adverse GI 
events. The risk for adverse cardiovascular events increased with 
age among persons undergoing colonoscopy, but these rates did 
not significantly differ from those in the age- equivalent matched 
group. In a large- scale, population- based, prospective observa-
tional study of over 1.3 million US Medicare beneficiaries, the 
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excess 30 day risk for any adverse event in the colonoscopy 
group was 5.6 events per 1000 individuals (95% CI 4.4 to 6.8) 
in the 70–74 year age group and 10.3 per 1000 (95% CI 8.6 to 
11.1) in the 75–79 year age group.
Perhaps the most pertinent study is a large, retrospective 
cohort study of colonoscopic surveillance in the elderly.49 This 
showed a significantly lower CRC incidence among elderly 
patients undergoing surveillance compared with non- elderly 
patients (0.24 per 1000 person- years vs 3.61 per 1000 person- 
years; p<0 .001; HR for CRC 0.06, 95% CI 0.02 to 0.13; 
p<0.001). Moreover, both age 75 years and older and Charlson 
score of 2 were independently associated with increased risk of 
postprocedure hospitalisation (adjusted OR 1.28, 95% CI 1.07 
to 1.53; p=0.006, and 2.54, 95% CI 2.06 to 3.14; p<0.001, 
respectively).
Of note, these populations (that is, older people and those 
with comorbidity) are also least likely to derive any benefit from 
post- polypectomy surveillance. This should be considered when 
deciding on the appropriateness of surveillance for an individual.
lAy summAry
A lay summary to accompany these guidelines is provided in 
online supplementary appendix 4.
heredITAry CAnCer/PolyPosIs rIsK
Management of patients with a higher than average risk of 
CRC due to hereditary CRC syndromes, serrated polyposis 
syndrome and other high familial CRC risk are covered in sepa-
rate guidelines that have been developed by the BSG, ACPGBI 
and UK Cancer Genetics Group (UKCGG) (in press), and are not 
addressed within this guideline. Clinicians should refer to those 
guidelines in the following situations:
1. A family history of colorectal cancer:
a. A family history of one first degree relative diagnosed 
with CRC under 50 years, or
b. Two affected first- degree relatives diagnosed with CRC 
at any age.
2. A patient with personal history of CRC diagnosed under age 
50 years (early onset CRC).
3. A patient with a personal history of CRC diagnosed at any 
age, who also has a first degree relative diagnosed with CRC 
at any age.
4. Patients with multiple polyps, specifically: patients under 60 
years of age with at least 10 adenomas, or patients from 60 
years of age with at least 20 adenomas or at least 10 adeno-
mas and a family history of CRC or polyposis.
5. Patients with known or suspected inherited CRC predisposi-
tion syndromes including:
a. Lynch syndrome
b. Polyposis syndromes including serrated polyposis syn-
drome (SPS) and familial polyposis.
The separate hereditary guidelines will include recommenda-
tions for germline genetic testing for patients with early onset 
CRC, multiple polyps and SPS. The diagnostic criteria for 
SPS has been redefined in a 2019 update by the World Health 
Organization:
 ► Either: At least five serrated polyps proximal to the rectum 
all being ≥5 mm in size, with two or more ≥10 mm in size; 
or
 ► More than 20 serrated polyps of any size distributed 
throughout the large bowel, with at least five proximal to the 
rectum included in the final polyp count. The polyp count is 
cumulative over multiple colonoscopies.
ImPlemenTATIon oF GuIdelInes
It is important that these updated surveillance guidelines are 
effectively implemented to deliver benefits to patients and 
provide effective, higher value care. Not only will this ensure 
that patients receive appropriate surveillance, it will also ensure 
that patients who do not benefit from surveillance do not have 
unnecessary invasive procedures. Inappropriate surveillance 
also carries an opportunity cost, by preventing more effective 
use of endoscopy in a resource- constrained service, increasing 
the burden on endoscopy services and the NHS generally. The 
Joint Advisory Group on Gastrointestinal Endoscopy (JAG) will 
continue to assess that surveillance validation and waiting times 
are appropriate and linked to the unit’s endoscopy governance 
process. This is particularly important given historically poor 
adherence to surveillance guidelines.
Dissemination of the guidelines from national endoscopy stake-
holders to the endoscopy workforce will be done using a variety 
of electronic communications and web- based technologies to 
reach the target audience. Conference presentations, workshops 
and other educational fora will support this dissemination. In 
addition, a visual summary of the surveillance algorithm has 
been developed to allow easy understanding and implementa-
tion of the guidelines (online supplementary appendix 5).
By combining the serrated and adenomatous polyp count, 
these guidelines will reduce the need for histology review before 
determining appropriate surveillance; nevertheless, surveillance 
decision- making will still be dependent on review of the polyp 
histology at times. The inevitable delay between the colonoscopy 
and the histology report becoming available often undermines this 
process, as evidenced by audits of the appropriateness of surveil-
lance colonoscopy waiting lists.150 This longstanding systemic issue 
has been identified within the Getting It Right First Time (GIRFT) 
programme as an important quality improvement initiative, 
focused mainly on the process around clinical decision- making for 
surveillance. Part of the solution may come from improvements in 
IT software, to facilitate the review process, and the management 
of surveillance populations including call and recall of patients. 
However, the clinical review needs to be transparent (eg, within a 
virtual clinic) and to be recognised within job plans. The appoint-
ment of a trust surveillance lead, responsible for ensuring that 
robust systems are in place to deliver surveillance to other high- risk 
groups, may also improve guideline compliance.
In implementing these updated guidelines, healthcare organ-
isations are advised to review patients already on surveillance 
waiting lists to determine concordance with new guidance. 
There will be some patients who no longer meet the criteria 
for colonoscopic surveillance and clear strategies for informing 
patients and their responsible clinicians should be agreed locally.
optical diagnosis of diminutive polyps in context of the 
current guideline
Optical biopsy—the use of endoscopic appearances to decide 
on polyp histology—was approved by NICE in 2017, with the 
use of virtual chromoendoscopy for diminutive polyps ≤5 mm 
in size to guide the setting of surveillance intervals; however, 
stipulations for training, audit and accreditation were specified 
but have not yet been developed. The Bowel Scope programme 
also permitted in 2018 the use of a white light optical assessment 
to diagnose hyperplastic polyps in the rectum that may be left 
in situ, without formal training or accreditation.151 The ESGE 
also supported optical biopsy for diminutive polyps in 2014 with 
similar caveats to NICE, and a recent revision of that guideline 
with new data did not change their statement.152 153 There is 
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therefore support for optical biopsy to avoid unnecessary resec-
tion in the rectum, and to set surveillance intervals.
Recent data from the DISCOUNT study from the Netherlands 
in their bowel cancer screening programme suggest at least a 
proportion (59%) of endoscopists can reach and maintain perfor-
mance in optical biopsy adequate to replace histopathology after 
training and meet predefined performance thresholds.154 In the 
proportion of lost or uninterpretable polyps where a patho-
logical diagnosis cannot be made, polyps are assumed to be 
adenomas. When this is taken into account, pathological accu-
racy is very similar to the diagnostic accuracy of optical biopsy.155 
The remaining barrier to uptake of optical diagnosis in the UK is 
the lack of an available accreditation process. It is possible that 
computer vision/deep learning based approaches will become 
commercially available to support endoscopists in optical biopsy 
in the next few years.156 157
The current surveillance guidelines differ from previous guidelines 
in that small and diminutive serrated polyps and adenomas are consid-
ered together as risk equivalent for surveillance intervals, except for 
diminutive rectal hyperplastic polyps. Potentially this obviates the 
need for pathological review of diminutive lesions, which could 
simply be counted to determine whether surveillance was required 
or not. Such lesions ≤5 mm have a low risk of containing advanced 
pathology, and an exceptionally low risk of containing cancer, 5.6% 
and 0.07%, respectively.158 Diminutive SSLs also have a very low 
risk of containing dysplasia (≤5 mm, 0%; 6–9 mm, 6.0%; ≥10 mm, 
13.6%).159 So called “DISCARD- lite” or “location based” strate-
gies perform almost as well as traditional optical biopsy strategies 
in terms of setting surveillance intervals using older adenoma- only 
based guidelines, and their performance with the current guide-
lines is likely to be even better.160 161 Therefore, simply resecting 
and discarding, and counting the numbers of diminutive polyps, is 
potentially a safe and very cost- effective strategy to set surveillance 
intervals based on the current guidelines, requiring minimal “optical 
biopsy” for hyperplastic polyps in the rectum. This may encourage 
and facilitate the wider uptake of optical biopsy and DISCARD- type 
strategies in clinical practice, and avoid the need for accreditation.
Workload implications and impact of the new guidelines
Preliminary analysis of available datasets suggests that implementation 
of these new guidelines may reduce the number of people entering 
post- polypectomy surveillance to around a quarter to a third of that 
of the previous low-/intermediate-/high- risk cohort. This is primarily 
by removal of almost all the previous low- risk cohort, along with 
approximately half of the previous intermediate- risk cohort; all the 
previous high- risk cohort will enter surveillance. The new algorithm 
appears to discriminate well between those at low- and high- risk of 
long- term CRC and of AN on surveillance.
We estimate that around 10% of those undergoing an initial 
surveillance procedure will qualify for further surveillance. Overall, 
we estimate that colonoscopic surveillance workload for the post- 
polypectomy cohort will reduce to approximately 20% of the present 
level.
No formal cost- effectiveness analysis of the guidelines has 
been performed. It is clear, however, that implementation of 
these guidelines will free up colonoscopy capacity in the UK. 
The UK currently has constrained endoscopy capacity which, 
for example, limits the expansion of the screening programme 
to younger age groups. Additional capacity could be used in 
patient populations with higher pathology yields—for example, 
advanced neoplasia is found in 20–40% of FIT positive people 
undergoing screening,162 leading to a more cost- effective use of 
the current colonoscopy resource.
Key PerFormAnCe IndICATor
Adherence to post- polypectomy and post- cancer resection 
surveillance recommendations should be monitored at least 
annually. Non- compliant cases should be reviewed to determine 
whether the reason for deviation from surveillance recommen-
dations was clearly documented and clinically appropriate.
reseArCh quesTIons
Throughout the guideline development process, the GDG iden-
tified some of the key unanswered research questions and needs, 
which are listed below:
 ► Greater evidence of the effect of surveillance using long- 
term CRC incidence/mortality as the endpoints.
 ► Evidence or consensus on minimum surveillance yield 
threshold of advanced premalignant polyps that justifies 
surveillance being worthwhile, for example, by correlation 
between surveillance yields and long- term CRC incidence.
 ► More robust evidence of the effectiveness of surveillance in 
people with serrated polyps.
 ► Evidence of the effectiveness of surveillance using a 
combined serrated plus adenomatous polyp count.
 ► The impact of a high- quality (as opposed to “acceptable 
quality”) index colonoscopy on surveillance findings, and 
how this might be incorporated into future surveillance 
algorithms.
 ► Further research on the impact of histological completeness 
of excision on surveillance yields, and whether this variable 
should be incorporated into future surveillance algorithms.
 ► Development of a personalised surveillance prognostic 
algorithm.
 ► Relevance of surveillance for those under the current 
screening age limit, especially the very young (eg, under 35 
years old).
 ► Relevance of surveillance for those above the current 
screening age limit (ie, 75 years or older).
 ► Further research on “stop surveillance” criteria and on the 
benefit of ongoing surveillance beyond the first surveillance 
procedure.
 ► Further evidence for the potential use of FIT, other technol-
ogies or biomarkers for surveillance.
 ► Greater data on patient experience and patient preferences 
surrounding surveillance, including what affects compliance.
 ► Future health economics evaluation: Collection of long- 
term outcomes data for the polypectomy population to 
enable estimation of expected lifetime QALYs. In a situation 
where endoscopy capacity is constrained (such as in the UK) 
it may be useful to consider the relative benefits (expected 
lifetime QALYs) of allocation of capacity between sympto-
matic referrals, screening and surveillance.
GuIdelInes revIeW
We recommend that the guidelines should be considered for 
review 5–10 years from the date of publication. Any updates 
to the guidelines in the interim will be noted on the BSG and 
ACPGBI websites.
In memoriam
Professor Wendy Atkin, world- leading expert on cancer surveil-
lance, author of original BSG/ACPGBI guidelines, mentor and 
friend to us all.
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